{
"id":"mk19_b_gm_s1",
"subspecialtyId":"gm2",
"title":"Routine Care of the Healthy Patient",
"jsonContent":{
"type":"section",
"id":"mk19_b_gm_s1",
"title":{
"__html":"Routine Care of the Healthy Patient"
},
"titleNode":{
"type":"section-title",
"hlId":"692157",
"children":[
"Routine Care of the Healthy Patient"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_gm_s1_1",
"title":{
"__html":"History and Physical Examination"
},
"titleNode":{
"type":"section-title",
"hlId":"2689f7",
"children":[
"History and Physical Examination"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_gm_s1_1_1",
"title":{
"__html":"Periodic Health Examination"
},
"titleNode":{
"type":"section-title",
"hlId":"803613",
"children":[
"Periodic Health Examination"
]
},
"children":[
{
"type":"p",
"hlId":"1b7478",
"children":[
"The periodic health examination is defined as a regular medical visit, often on an annual basis, for the purposes of screening and prevention. Championed in the past by industry, insurance organizations, and organized medicine, the periodic health examination has become an expectation of physicians and patients alike. Patients have become accustomed to a comprehensive head-to-toe physical examination as well as recommendations for screening for disease, blood tests, and other routine testing. Although evidence suggests periodic health examinations may improve surrogate outcomes, such as reduction in cardiovascular risk factors and increased receipt of preventive services, there is no evidence that they reduce mortality or other patient-important outcomes. A 2019 Cochrane systematic review confirmed that general health checks may result in more new diagnoses but do not reduce morbidity, hospitalizations, or mortality. According to a 2007 estimate, periodic health examinations also have a substantial financial impact, costing $5.2 billion annually without including costs of additional testing, office visits, or missed work. Overdiagnosis and overtreatment are other potential drawbacks to periodic health checks. The U.S. Preventive Services Task Force (USPSTF), the Choosing Wisely campaign, and the Canadian Task Force on the Periodic Health Examination recommend against performing general health checks that include a comprehensive examination and laboratory testing for asymptomatic adults. However, some countries, including the United Kingdom, Germany, and Japan, continue to recommend periodic health examinations."
]
},
{
"type":"p",
"hlId":"096033",
"children":[
"Despite the recommendation to avoid the periodic health examination, the practice may offer value that is difficult to measure in clinical trials. It provides dedicated time for screening, immunizations, and healthy lifestyle counseling and may strengthen physician-patient relationships and patient adherence to physician recommendations. In 2011, Medicare introduced an annual wellness visit to develop or update a personalized prevention plan; however, a study of these visits did not show improvements in care. In practices that do not routinely use periodic health examinations, automated reminder systems, online portals, and clinical assistants can help prompt receipt of indicated preventive services to patients at home or during focused visits."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_1_2",
"title":{
"__html":"Routine History and Physical Examination"
},
"titleNode":{
"type":"section-title",
"hlId":"47b92a",
"children":[
"Routine History and Physical Examination"
]
},
"children":[
{
"type":"p",
"hlId":"ba2d38",
"children":[
"In the modern era of technological advances, such as online health messaging, electronic health records, and telemedicine, as well as physician time constraints and pressure to meet quality measures, the practice of medicine may seem more depersonalized. Evidence reviews have identified good practices to enhance physician rapport and connection with patients, most of which may not add significant time to the visit and could potentially save time in the long run by setting expectations for visits and building trust. Useful strategies include reviewing relevant information ahead of time, structuring brief reflective pauses before each visit, providing a warm greeting, mutually setting a clear agenda, and practicing active listening."
]
},
{
"type":"p",
"hlId":"d44939",
"children":[
"Obtaining a basic history as well as a focused history of presenting problems is essential in establishing a clinician-patient relationship and understanding the patient's health, concerns, and expectations ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t01",
"wrapId":"1",
"children":[
"Table 1"
]
}
]
},
")"
]
},
". Patients may be sensitive about sharing certain information, such as substance use and sexual practices; open and nonjudgmental communication can encourage sharing. Clinicians should preface these inquiries by informing the patient that these questions are asked of everyone, the information is necessary to provide the best care, and responses are confidential. A focused history of the primary reasons for the visit should also be obtained. It is often helpful to start with an open-ended question or statement, such as, “Tell me about your knee pain,” which often results in more information sharing than does directive questioning. A commonly taught mnemonic to elicit other relevant information is OLDCARTS (Onset, Location/radiation, Duration, Character, Aggravating factors, Relieving factors, Timing, Severity). It is often helpful to ask the patient, “What do you think is going on?”"
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_gm_t01"
]
},
{
"type":"p",
"hlId":"385652",
"children":[
"A focused physical examination should address the patient's concerns and relevant historical findings. Physical examination plays a large role in diagnosis. Irrespective of gender presentation, physicians should provide care for the present anatomy in a sensitive, respectful, and affirming manner. Regularly obtaining height and weight (to calculate BMI) as well as blood pressure is universally recommended. In addition, pulse palpation in individuals older than 65 years has been found effective for detection of atrial fibrillation. In asymptomatic patients, the USPSTF recommends against routine abdominal, testicular, and bimanual pelvic examinations for cancer screening. Routine cardiac and lung auscultation, thyroid palpation, skin examination, visual acuity assessment, and hearing assessment may be appropriate as part of a comprehensive physical examination in persons at increased risk. Relatively little harm arises from these examinations save for the opportunity cost of providing another service that may be more valuable and the theoretical risk for overtesting and overdiagnosis. Routine testing in asymptomatic patients, such as screening complete blood count, urinalysis, and ECG in patients at low risk for cardiovascular disease, is not recommended. The USPSTF concluded that there is insufficient evidence to assess the benefits or harms of screening for atrial fibrillation with ECG or other recording modalities, including wearable devices and applications."
]
},
{
"type":"p",
"hlId":"2469ba",
"children":[
"Preparticipation physical examination is often required for adolescents and young adults before participation in organized sports. In conjunction with the American Academy of Family Physicians and several professional sports medicine organizations, the American Academy of Pediatrics (AAP) created the Preparticipation Physical Evaluation. In addition, free templates for history, physical examination, and clearance forms are available on the AAP website (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.aap.org/en-us/about-the-aap/Committees-Councils-Sections/Council-on-sports-medicine-and-fitness/Pages/PPE.aspx",
"target":"_blank"
},
"children":[
"www.aap.org/en-us/about-the-aap/Committees-Councils-Sections/Council-on-sports-medicine-and-fitness/Pages/PPE.aspx"
]
},
"). Mandatory components include evaluating for exertional symptoms, family history of premature or sudden cardiac death, and presence of a heart murmur."
]
},
{
"type":"p",
"hlId":"ffb2c5",
"children":[
"Digital stethoscopes, point-of-care ultrasonography, smart phone applications, and other technological advances are gradually becoming more commonplace in the physical examination. Several of these tools, particularly point-of-care ultrasonography, may improve diagnosis, although there is the potential for overdiagnosis as well."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"9e6e06",
"hvc":true,
"children":[
"The periodic health examination may help maintain a strong patient-provider relationship and improve surrogate outcomes, such as reduction in cardiovascular risk factors and increased receipt of preventive services; however, the periodic health examination has not been shown to reduce mortality or other patient-important outcomes."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2",
"title":{
"__html":"Screening"
},
"titleNode":{
"type":"section-title",
"hlId":"db7551",
"children":[
"Screening"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_gm_s1_2_1",
"title":{
"__html":"Principles of Screening"
},
"titleNode":{
"type":"section-title",
"hlId":"5f553a",
"children":[
"Principles of Screening"
]
},
"children":[
{
"type":"p",
"hlId":"30f289",
"children":[
"Levels of prevention have traditionally been categorized as primary, secondary, and tertiary. Primary prevention is prevention of disease or injury before it occurs (for example, through immunization). Secondary prevention is early detection and treatment of disease in asymptomatic patients to slow or stop disease progression. Most screening tests, such as those for colorectal and breast cancers, are secondary prevention measures. Tertiary prevention involves reducing morbidity and mortality due to established disease, such as cardiac rehabilitation after myocardial infarction."
]
},
{
"type":"p",
"hlId":"a8f776",
"children":[
"Screening is appropriate for common conditions for which (1) early intervention can decrease morbidity and mortality and (2) safe, acceptable, widely available, and reasonably priced screening tests exist. Screening tests must also have adequate sensitivity and specificity to minimize false-positive and false-negative results. Population-based screening and case-finding are often confused. Case-finding is a strategy of targeted testing that relies on clinical judgment of appropriateness and potential benefit for a given patient that meets evidence-based criteria for inclusion in a high-risk group. The evidence that case-finding improves morbidity or mortality is often weak or absent."
]
},
{
"type":"p",
"hlId":"d018c1",
"children":[
"The effectiveness of screening tests in reducing morbidity and mortality is evaluated through clinical trials; however, studies of screening tests are problematic and subject to three types of bias. Lead-time bias occurs when early detection artificially results in an increase in measured survival. The time between early detection and clinical diagnosis is mistakenly counted as survival time; however, only the measured time with diagnosed disease, not survival time, has increased ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_gm_f01",
"wrapId":"2",
"children":[
"Figure 1"
]
}
]
},
")"
]
},
". Using disease-specific mortality rates rather than survival time as the primary outcome in studies of screening tests can help minimize lead-time bias. Length-time bias occurs when screening detects more cases of disease with a prolonged asymptomatic phase than cases of disease with a short asymptomatic phase. Slowly progressive disease is more likely than aggressive disease to be detected with screening, leading to an overestimation of survival benefit in those with screen-detected disease. An example of length-time bias is the detection of indolent and slow-growing prostate cancer rather than more aggressive tumors with a short asymptomatic phase, with a resultant overestimation of survival benefit. Overdiagnosis, or finding and treating illness that otherwise would not have become clinically apparent or caused harm in the patient's lifetime, is an extreme example of length-time bias. Overdiagnosis is an increasingly recognized harm of breast and prostate cancer screening and may also occur with incidental detection of thyroid and kidney cancers on imaging studies. Selection bias, also referred to as volunteer bias, referral bias, or compliance bias, occurs when patients who undergo screening tests are healthier and more interested in their health than nonadherent patients or the general population. Intention-to-treat analyses, in which patients are analyzed according to their original group assignment in randomized clinical trials regardless of intervention received, reduce selection bias."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_gm_f01"
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_2",
"title":{
"__html":"Screening Recommendations for Adults"
},
"titleNode":{
"type":"section-title",
"hlId":"2275b8",
"children":[
"Screening Recommendations for Adults"
]
},
"children":[
{
"type":"p",
"hlId":"2318ea",
"children":[
"The USPSTF and many specialty societies routinely aggregate and review available evidence to inform clinical practice guidelines for screening, counseling, and use of preventive medications. The USPSTF recommendations are available at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.uspreventiveservicestaskforce.org",
"target":"_blank"
},
"children":[
"www.uspreventiveservicestaskforce.org"
]
},
". The Emergency Care Research Institute (ECRI) is designated an Evidence-based Practice Center by the Agency for Healthcare Research and Quality (AHRQ) and maintains a clinical practice guideline repository at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://guidelines.ecri.org",
"target":"_blank"
},
"children":[
"https://guidelines.ecri.org"
]
},
". The American College of Physicians (ACP) has developed several types of clinical recommendations, including clinical practice guidelines, clinical guidance statements, best practice advice, and recommendations regarding high-value care, all of which are available at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.acponline.org/clinical-information/guidelines",
"target":"_blank"
},
"children":[
"www.acponline.org/clinical-information/guidelines"
]
},
". Although there is much agreement among screening recommendations, guidelines often disagree when (1) sufficient evidence is lacking and expert opinion plays a larger role or (2) potential benefits and harms both exist and the balance depends on a person's risk, preferences, and values."
]
},
{
"type":"p",
"hlId":"496adf",
"children":[
"An additional resource to help clinicians identify appropriate screening tests and preventive services is Prevention TaskForce, an electronic tool that is available in Web- and mobile application–based formats at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.uspreventiveservicestaskforce.org/apps/",
"target":"_blank"
},
"children":[
"www.uspreventiveservicestaskforce.org/apps/"
]
},
". With this tool, users can select USPSTF-recommended practices on the basis of patient age, sex, and other characteristics (such as tobacco use or pregnancy)."
]
},
{
"type":"p",
"hlId":"c76e0a",
"children":[
"Screening recommendations frequently change as supportive evidence emerges. It is important to be aware of changes in recommendations, reflect on the rationale and implications of the changes, and incorporate these changes appropriately into practice."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3",
"title":{
"__html":"Specific Screening Tests"
},
"titleNode":{
"type":"section-title",
"hlId":"a7fc80",
"children":[
"Specific Screening Tests"
]
},
"children":[
{
"type":"p",
"hlId":"641ba3",
"children":[
"The following section describes screening recommendations from the USPSTF and other organizations. The grading system of the USPSTF (A, B, C, or D, or I statement) is explained in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t02",
"wrapId":"3",
"children":[
"Table 2"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_gm_t02"
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_1",
"title":{
"__html":"Screening for Chronic Diseases"
},
"titleNode":{
"type":"section-title",
"hlId":"7e6e9f",
"children":[
"Screening for Chronic Diseases"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_1_1",
"title":{
"__html":"Abdominal Aortic Aneurysm"
},
"titleNode":{
"type":"section-title",
"hlId":"a2a856",
"children":[
"Abdominal Aortic Aneurysm"
]
},
"children":[
{
"type":"p",
"hlId":"64188a",
"children":[
"The USPSTF recommends one-time abdominal ultrasonography to screen for abdominal aortic aneurysm (AAA) in all men aged 65 to 75 years who have ever smoked (grade B). Ever-smokers are commonly defined as persons who have smoked more than 100 cigarettes (five packs) in their lifetime. Surgical repair is usually considered once the diameter exceeds 5.5 cm. The number needed to screen to prevent one death from AAA in this population is 714. In men aged 65 to 75 years who have never smoked, selective screening is recommended (grade C), especially in those with a first-degree relative with a history of treated or ruptured AAA. The USPSTF assessed the benefits of screening for AAA in women aged 65 to 75 years who have ever smoked as uncertain and makes no recommendation regarding screening in this population (I statement). This likely reflects the low prevalence of AAA in women (1%) versus men (4%-7%) as well as limited evidence to recommend against screening. The USPSTF specifically recommends against routine screening in women who have never smoked and who have no family history of AAA (grade D). Women, however, may have higher risk for rupture with AAAs of smaller sizes."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_1_2",
"title":{
"__html":"Cardiovascular and Cerebrovascular Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"e37a6a",
"children":[
"Cardiovascular and Cerebrovascular Disease"
]
},
"children":[
{
"type":"p",
"hlId":"3ea8f1",
"children":[
"Cardiovascular risk assessment is performed in asymptomatic adults to evaluate a patient's risk for future cardiac events; it does not identify preexisting disease and is therefore considered separate from screening (see ",
{
"type":"cross-reference",
"target":"mk19_b_cv_s1_3",
"children":[
"MKSAP 19 Cardiovascular Medicine"
]
},
")."
]
},
{
"type":"p",
"hlId":"51511d",
"children":[
"The USPSTF does not recommend screening for coronary artery disease with either resting or exercise ECG in asymptomatic patients at low risk, defined by the USPSTF as a 10-year cardiovascular event risk of less than 10% using the Pooled Cohort Equations (grade D). In patients at intermediate or high risk for such events, evidence was inadequate to assess the relative benefits and harms of screening (I statement). Similarly, the ACP recommends against screening low-risk and asymptomatic adults with resting ECG or stress testing. No specialty organization recommends screening these populations with coronary calcium scoring or coronary angiography."
]
},
{
"type":"p",
"hlId":"f589f0",
"children":[
"The USPSTF also does not recommend screening for carotid artery stenosis in the general adult population (grade D). The rationale for this recommendation is based on the very low prevalence of carotid stenosis (0.5%-1%) and resulting high rate of false-positive results yielded by commonly used ultrasonography. Auscultation of the neck for carotid bruits is ineffective for screening as well. Screening for carotid stenosis in asymptomatic patients could lead to harm as a result of complications from angiographic studies or endarterectomy."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_1_3",
"title":{
"__html":"Cognitive Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"39d820",
"children":[
"Cognitive Disorders"
]
},
"children":[
{
"type":"p",
"hlId":"bfa4af",
"children":[
"The USPSTF assessed the benefits of screening for cognitive impairment as uncertain (I statement) owing to lack of high-quality evidence. Various screening tests with high predictive value are available (see ",
{
"type":"cross-reference",
"target":"mk19_a_gm_s10_1_5",
"children":[
"MKSAP 19 General Internal Medicine 1"
]
},
"). However, it is uncertain that early detection changes or improves clinical outcomes."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_1_4",
"title":{
"__html":"Depression and Anxiety"
},
"titleNode":{
"type":"section-title",
"hlId":"e3d63d",
"children":[
"Depression and Anxiety"
]
},
"children":[
{
"type":"p",
"hlId":"dd7ef9",
"children":[
"The USPSTF suggests that all adults, including pregnant and postpartum women, be screened for depression, with adequate systems in place for subsequent assessment, treatment, and follow-up (grade B). Most adults can be screened with the brief PHQ-2, which consists of two questions: “During the past 2 weeks, how often have you been bothered by feeling down, depressed, or hopeless?” and “During the past 2 weeks, have you often been bothered by having little interest or pleasure in doing things?",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"”"
]
},
" Responses to each question may be scaled (0-3) or dichotomous (yes/no). A total score for both questions of 3 or greater or a single “yes” response indicates the possibility of clinically significant depression. Patients with a positive screening result should be formally assessed for depression and complete the PHQ-9, which can be used for monitoring of depression."
]
},
{
"type":"p",
"hlId":"37afb2",
"children":[
"Other screening instruments may be more accurate for screening in specific patient populations; these include the Geriatric Depression Scale in older adults and the Edinburgh Postnatal Depression Scale in postpartum and pregnant women."
]
},
{
"type":"p",
"hlId":"02d8b9",
"children":[
"Effective interventions are available to prevent peripartum depression, but there are no validated risk assessment tools to identify women who might benefit. The USPSTF suggests that women with increased risk can be identified by one or more of the following risk factors: a history of depression, current depressive symptoms that do not reach a diagnostic threshold, low income, adolescent or single parenthood, recent intimate partner violence, elevated anxiety symptoms, or a history of significant negative life events."
]
},
{
"type":"p",
"hlId":"10e187",
"children":[
"Although the USPSTF does not provide a recommendation regarding screening for anxiety, the Women's Preventive Services Initiative suggests screening for anxiety in all women, including those who are pregnant or in the postpartum period. This can be performed in conjunction with screening for depression."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_1_5",
"title":{
"__html":"Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"983bb7",
"children":[
"Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"674c06",
"children":[
"The USPSTF recommends screening for diabetes mellitus in adults aged 35 to 70 years who are overweight or obese (grade B). Screening can be accomplished by measuring fasting plasma glucose or hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
"."
]
},
{
"type":"p",
"hlId":"e8b74d",
"children":[
"In contrast to the USPSTF, the American Diabetes Association (ADA) recommends that screening be performed in patients of any age who are overweight or obese and have one or more risk factors for diabetes ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t03",
"wrapId":"4",
"children":[
"Table 3"
]
}
]
},
")"
]
},
". The ADA also recommends screening all adults beginning at age 35 years, regardless of risk factors, and repeating screening at 3-year intervals. Patients with prediabetes (hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" ≥5.7%, impaired glucose tolerance, or impaired fasting glucose) should be screened annually."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_gm_t03"
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_1_6",
"title":{
"__html":"Dyslipidemia"
},
"titleNode":{
"type":"section-title",
"hlId":"5a1567",
"children":[
"Dyslipidemia"
]
},
"children":[
{
"type":"p",
"hlId":"eadf59",
"children":[
"The USPSTF recommends calculating the cardiovascular disease risk in adults aged 40 to 75 years using the Pooled Cohort Equations. This requires measurement of serum lipid levels to determine risk for an atherosclerotic cardiovascular disease (ASCVD) event."
]
},
{
"type":"p",
"hlId":"51d48d",
"children":[
"For adults 40 to 75 years of age, the American College of Cardiology (ACC)/American Heart Association (AHA) also recommends routine assessment traditional cardiovascular risk factors and calculation of the 10-year risk for ASCVD by using the Pooled Cohort Equations. For adults 20 to 39 years of age, ACC/AHA believes that it is reasonable to assess traditional ASCVD risk factors at least every 4 to 6 years."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_1_7",
"title":{
"__html":"Hypertension"
},
"titleNode":{
"type":"section-title",
"hlId":"01da3e",
"children":[
"Hypertension"
]
},
"children":[
{
"type":"p",
"hlId":"24c84f",
"children":[
"The USPSTF supports screening all adults beginning at age 18 years for hypertension (grade A). Screening should occur annually in adults aged 40 years or older and in younger adults at increased risk. Screening should otherwise occur at 3- to 5-year intervals. For more information, see ",
{
"type":"cross-reference",
"target":"mk19_a_np_s4_5",
"children":[
"MKSAP 19 Nephrology"
]
},
"."
]
},
{
"type":"p",
"hlId":"bef160",
"children":[
"The predictive value of screening for hypertension is improved through multiple serial measurements in a variety of settings. Before treatment is initiated, when possible and in the absence of severe hypertension or end-organ damage, the diagnosis should be confirmed with blood pressure measurements outside of the clinical setting, such as ambulatory or home blood pressure monitoring."
]
},
{
"type":"p",
"hlId":"cad504",
"children":[
"The ACC/AHA recommend annual evaluation of patients with normal blood pressure (<120/<80 mm Hg). Adults with elevated blood pressure or stage 1 hypertension (130 to 139/80 to 89 mm Hg) who have an estimated 10-year ASCVD risk less than 10% should be managed with nonpharmacologic therapy and have a repeat blood pressure evaluation within 3 to 6 months."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_1_8",
"title":{
"__html":"Obesity"
},
"titleNode":{
"type":"section-title",
"hlId":"9f8251",
"children":[
"Obesity"
]
},
"children":[
{
"type":"p",
"hlId":"ccebad",
"children":[
"The USPSTF no longer recommends screening for obesity but does recommend referring or initiating weight loss interventions for adults with a BMI of 30 or higher (grade B).The ACC, the AHA, and The Obesity Society recommend annual screening with BMI and waist circumference measurements."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_1_9",
"title":{
"__html":"Obstructive Sleep Apnea"
},
"titleNode":{
"type":"section-title",
"hlId":"0dc974",
"children":[
"Obstructive Sleep Apnea"
]
},
"children":[
{
"type":"p",
"hlId":"f56515",
"children":[
"According to the USPSTF, evidence is insufficient to assess the balance of benefits and harms of screening for obstructive sleep apnea in asymptomatic adults with the currently available tools (I statement). Because obstructive sleep apnea is widely underrecognized, clinicians should have a low threshold for investigating for sleep apnea in patients who have symptoms consistent with the disease (see ",
{
"type":"cross-reference",
"target":"mk19_b_pm_s8_3_3",
"children":[
"MKSAP 19 Pulmonary and Critical Care Medicine"
]
},
")."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_1_10",
"title":{
"__html":"Osteoporosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c9459d",
"children":[
"Osteoporosis"
]
},
"children":[
{
"type":"p",
"hlId":"892d06",
"children":[
"The USPSTF and the American College of Obstetricians and Gynecologists (ACOG) recommend screening for osteoporosis in all women aged 65 years or older and in women younger than 65 years who are at increased risk for osteoporosis, as determined by a formal clinical risk assessment tool. The Fracture Risk Assessment (FRAX) is a commonly used clinical risk assessment tool, available at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.shef.ac.uk/FRAX",
"target":"_blank"
},
"children":[
"www.shef.ac.uk/FRAX"
]
},
". Women who have a 10-year FRAX risk for major osteoporotic fracture equal to or higher than that of a 65-year-old woman without additional risk factors (10-year risk of 8.4%) should undergo screening for osteoporosis. Screening can be accomplished with bone mineral density measurement, most commonly with dual-energy x-ray absorptiometry of the hip and lumbar spine. Although the USPSTF makes no recommendation on rescreening, ACOG suggests repeat osteoporosis screening after an interval of at least 2 years in postmenopausal patients with significant changes in risk profile or initial bone mineral density test results that approached the threshold to treat."
]
},
{
"type":"p",
"hlId":"461ad9",
"children":[
"The USPSTF concludes that evidence is insufficient to recommend routine screening for osteoporosis in men to reduce the risk for fractures (I statement); however, the National Osteoporosis Foundation recommends osteoporosis screening in men aged 70 years or older. Screening may be considered in younger men at high risk for osteoporosis on the basis of risk factors, such as low body weight, recent weight loss, physical inactivity, use of oral glucocorticoids, previous fragility fracture, alcohol use, and androgen deprivation through pharmacologic agents or orchiectomy."
]
},
{
"type":"p",
"hlId":"a8d2e6",
"children":[
"Risk assessment and screening for osteoporosis are further discussed in ",
{
"type":"cross-reference",
"target":"mk19_b_en_s7_4_1",
"children":[
"MKSAP 19 Endocrinology and Metabolism"
]
},
"."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_1_11",
"title":{
"__html":"Thyroid Dysfunction"
},
"titleNode":{
"type":"section-title",
"hlId":"47a1e0",
"children":[
"Thyroid Dysfunction"
]
},
"children":[
{
"type":"p",
"hlId":"e3e002",
"children":[
"The USPSTF concludes that evidence is insufficient to recommend for or against screening for thyroid dysfunction (I statement). The American Thyroid Association and the American Association of Clinical Endocrinologists, however, recommend measuring thyroid-stimulating hormone in individuals at risk for hypothyroidism (for example, personal history of autoimmune disease, neck radiation, or thyroid surgery); they additionally recommend considering screening in adults aged 60 years or older."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"1aa573",
"children":[
"The U.S. Preventive Services Task Force supports routine screening for depression, hypertension, tobacco use, and alcohol misuse in asymptomatic, average-risk adults."
]
},
{
"type":"keypoint",
"hlId":"b23f27",
"children":[
"Adults aged 35 to 70 years who are overweight or obese should be screened for diabetes mellitus, according to the U.S. Preventive Services Task Force."
]
},
{
"type":"keypoint",
"hlId":"4a00f4",
"children":[
"Lipid screening is indicated in adults aged 40 to 75 years for the purposes of calculating 10-year risk for atherosclerotic cardiovascular disease and guiding initiation of statin therapy for primary prevention."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_2",
"title":{
"__html":"Screening for Infectious Diseases"
},
"titleNode":{
"type":"section-title",
"hlId":"460425",
"children":[
"Screening for Infectious Diseases"
]
},
"children":[
{
"type":"p",
"hlId":"e6e194",
"children":[
"Screening for infectious diseases is primarily recommended for individuals at increased risk ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t04",
"wrapId":"5",
"children":[
"Table 4"
]
}
]
}
]
},
" and ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t05",
"wrapId":"5",
"children":[
"Table 5"
]
}
]
},
")"
]
},
", although there are several diseases for which average-risk patients should be screened."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_gm_t04",
"mk19_b_gm_t05"
]
},
{
"type":"p",
"hlId":"55149f",
"children":[
"According to the USPSTF, screening for chlamydia and gonorrhea should be performed in all sexually active women aged 24 years or younger because of increased prevalence in this population. In the absence of studies on screening intervals, the USPSTF believes that repeat screening is reasonable in patients whose sexual history reveals new or persistent risk factors since the last negative test result. Screening for these diseases in men of this age and demographic is not recommended (I statement) owing to lack of evidence to support benefits of screening."
]
},
{
"type":"p",
"hlId":"92a12c",
"children":[
"One-time screening for hepatitis C virus should be completed in all patients aged 18 to 79 years. The USPSTF does not promote screening in patients older than 79 years, although the CDC does not specify an upper age limit. Patients with risk factors should also be retested regardless of age. Screening is accomplished by testing for antibodies to the disease, followed by polymerase chain reaction viral load testing if results of initial testing are positive (see ",
{
"type":"cross-reference",
"target":"mk19_a_gi_s6_2_3",
"children":[
"MKSAP 19 Gastroenterology and Hepatology"
]
},
")."
]
},
{
"type":"p",
"hlId":"0aea77",
"children":[
"The USPSTF recommends that all persons aged 15 to 65 years receive one-time HIV screening regardless of risk, and CDC recommends routine HIV screening for all persons aged 13 to 64 years. Pregnancy is an indication for repeat screening for HIV infection. The USPSTF suggests repeat screening of persons at increased risk for HIV (such as men who have sex with men and active injection drug users) but does not specify the interval for repeat screening. The CDC recommends at least annual screening for men who have sex with men but notes that more frequent screening may be appropriate in other populations. Combination HIV antibody immunoassay/p24 antigen testing is recommended for screening. Diagnosis of HIV is discussed in ",
{
"type":"cross-reference",
"target":"mk19_a_id_s18_3",
"children":[
"MKSAP 19 Infectious Disease"
]
},
"."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"f38e90",
"children":[
"The U.S. Preventive Services Task Force recommends that all persons aged 15 to 65 years receive one-time HIV screening and persons 18 to 79 years receive one-time hepatitis C screening regardless of risk."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_3",
"title":{
"__html":"Screening for Substance Use Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"00a152",
"children":[
"Screening for Substance Use Disorders"
]
},
"children":[
{
"type":"p",
"hlId":"99fb2c",
"children":[
"The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral intervention and pharmacotherapy for tobacco cessation (grade A) (see ",
{
"type":"cross-reference",
"target":"mk19_a_gm_s9_5_1",
"children":[
"MKSAP 19 General Internal Medicine 1"
]
},
"). The ACC/AHA recommend assessment of tobacco use at every visit."
]
},
{
"type":"p",
"hlId":"01d397",
"children":[
"The USPSTF supports asking all adults about alcohol misuse and providing persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce alcohol misuse (grade B). Screening instruments to identify harmful drinking include the Alcohol Use Disorders Identification Test (AUDIT), the AUDIT-Consumption (AUDIT-C), and single-item screening. The AUDIT (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://pubs.niaaa.nih.gov/publications/Audit.pdf",
"target":"_blank"
},
"children":[
"https://pubs.niaaa.nih.gov/publications/Audit.pdf"
]
},
") is a validated 10-item screening test that takes approximately 2 to 3 minutes to administer; the AUDIT-C is a briefer (three-item) version of the AUDIT. With single-item screening, the clinician asks, “How many times in the past year have you had five [four for women] or more drinks in 1 day?” A positive test result, defined as any answer other than “zero,” has a sensitivity and specificity of approximately 80% for unhealthy alcohol use."
]
},
{
"type":"p",
"hlId":"63f80c",
"children":[
"The USPSTF recommends asking adults aged 18 years or older about the use of illegal or nonprescribed psychoactive drugs if the physician is also able to offer treatment or refer the patient to treatment. Screening tools include the Drug Abuse Screening Test (DAST-10) (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.thenationalcouncil.org/wp-content/uploads/2021/04/DAST_-_10.pdf",
"target":"_blank"
},
"children":[
"http://www.thenationalcouncil.org/wp-content/uploads/2021/04/DAST_-_10.pdf"
]
},
") and the CAGE questionnaire expanded to include drugs (CAGE-AID) (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.hrsa.gov/behavioral-health/cage-aid-substance-abuse-screening-tool",
"target":"_blank"
},
"children":[
"www.hrsa.gov/behavioral-health/cage-aid-substance-abuse-screening-tool"
]
},
")."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_4",
"title":{
"__html":"Screening for Abuse"
},
"titleNode":{
"type":"section-title",
"hlId":"f0716f",
"children":[
"Screening for Abuse"
]
},
"children":[
{
"type":"p",
"hlId":"38f8bc",
"children":[
"The USPSTF recommends screening for intimate partner violence in all women of childbearing age and referring to appropriate social services if screening is positive (grade B). Available screening tools include the Hurt, Insult, Threaten, Scream (HITS); Ongoing Abuse Screen/Ongoing Violence Assessment Tool (OAS/OVAT); Slapped, Threatened, and Throw (STaT); Humiliation, Afraid, Rape, Kick (HARK); Modified Childhood Trauma Questionnaire–Short Form (CTQ-SF); and Woman Abuse Screening Tool (WAST)."
]
},
{
"type":"p",
"hlId":"27c8aa",
"children":[
"The USPSTF states that evidence is currently insufficient to recommend universal screening in this population (I statement)."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_5",
"title":{
"__html":"Screening for Cancer"
},
"titleNode":{
"type":"section-title",
"hlId":"c5c56f",
"children":[
"Screening for Cancer"
]
},
"children":[
{
"type":"p",
"hlId":"c2cb78",
"children":[
"This section discusses cancer screening in asymptomatic, average-risk persons. Screening for cancer in patients at high risk is covered in the respective specialty books of MKSAP 19."
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_5_1",
"title":{
"__html":"Breast Cancer"
},
"titleNode":{
"type":"section-title",
"hlId":"a6e49f",
"children":[
"Breast Cancer"
]
},
"children":[
{
"type":"p",
"hlId":"a35355",
"children":[
"The balance of benefits and harms of screening mammography in average-risk women has shifted with the advent of increasingly effective breast cancer treatments, which reduce the benefits of early detection, as well as emerging information about overdiagnosis. Women at average risk include those without a personal history of breast cancer or a high-risk breast lesion, genetic mutations conferring elevated risk for breast cancer, or a history of radiation to the chest as a child. In average-risk women aged 50 to 74 years, there is a clear benefit to screening mammography, and all breast cancer guidelines recommend screening mammography in this age group. Specific screening recommendations, however, vary by specialty society ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t06",
"wrapId":"6",
"children":[
"Table 6"
]
}
]
}
]
},
", ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"video-link",
"target":"mk19_b_gm_v01",
"wrapId":"6",
"children":[
"Video 1"
]
}
]
},
"). The USPSTF recommends biennial screening mammography, which imparts most of the benefits of annual mammography with fewer harms. In women younger than 50 years or aged 75 years or older, the balance of benefits and harms is less clear, and screening recommendations vary widely. Breast cancer screening with clinical breast examination is not recommended."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_gm_t06",
"mk19_b_gm_v01"
]
},
{
"type":"p",
"hlId":"a936ab",
"children":[
"Shared decision making with consideration of the patient's level of risk, values, and preferences guides the screening decision. The benefit of screening is largest in women aged 60 to 69 years and is substantially lower for younger and older women ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t07",
"wrapId":"7",
"children":[
"Table 7"
]
}
]
},
")"
]
},
". Potential harms of screening include false-positive results and overdiagnosis. For patients starting mammography at age 40 or 50 years, the 10-year cumulative false-positive rates are 42% with biennial screening and 61% with annual screening. Such results may cause unnecessary biopsies and substantial patient anxiety."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_gm_t07"
]
},
{
"type":"p",
"hlId":"d1b4ce",
"children":[
"Approximately 50% of women have dense breasts on mammography, resulting in decreased sensitivity of mammography for breast cancer (more so with film than digital mammography). Radiologists use the Breast Imaging and Reporting Data System (BI-RADS) to categorize mammography findings and assess breast density (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s7_1_1",
"children":[
"Women's Health"
]
},
"). Increased breast density is associated with an increased risk for breast cancer, but patients with dense breasts should not be considered at high risk for breast cancer on the basis of dense breasts alone. For women in whom increased breast density is the sole risk factor for breast cancer, there is no evidence that adding MRI or ultrasonography to mammography affects breast cancer mortality, and most guidelines conclude that evidence is insufficient to recommend adjunctive screening when dense breasts are present. The American College of Radiology, however, notes that ultrasonography may be considered in this circumstance. Furthermore, some states have legislated that women be informed when dense breasts are noted on imaging and that this may increase the risk for breast cancer. Women with dense breasts should undergo further risk stratification; for those at high risk, additional screening may be considered (see ",
{
"type":"cross-reference",
"target":"mk19_a_on_s2_3",
"children":[
"MKSAP 19 Oncology"
]
},
")."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_5_2",
"title":{
"__html":"Prostate Cancer"
},
"titleNode":{
"type":"section-title",
"hlId":"0ec7af",
"children":[
"Prostate Cancer"
]
},
"children":[
{
"type":"p",
"hlId":"4f8086",
"children":[
"Screening for prostate cancer in asymptomatic, average-risk men has been controversial, and recommendations among professional organizations continue to evolve ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t08",
"wrapId":"8",
"children":[
"Table 8"
]
}
]
},
")"
]
},
". For men aged 55 to 69 years, the USPSTF recommends that clinicians engage in a discussion of the potential benefits versus harms of screening for prostate cancer before ordering testing. The USPSTF recommends that clinicians should not screen men unless they express a preference for screening and recommends against routine prostate-specific antigen (PSA)–based screening for prostate cancer in men aged 70 years or older."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_b_gm_t08"
]
},
{
"type":"p",
"hlId":"d4bb1f",
"children":[
"Benefits of screening for men aged 55 to 69 years include prevention of one prostate cancer–related death for every 1000 men screened for 10 years (i.e., the number needed to screen is 1000). Risks include overdiagnosis, overtreatment, and false-positive results that trigger unnecessary biopsies and patient anxiety. Estimated rates of overdiagnosis and overtreatment vary widely."
]
},
{
"type":"p",
"hlId":"7909c5",
"children":[
"If the decision is made to proceed with screening, the American Urological Association (AUA) recommends choosing less frequent screening intervals (≥2 years), which may reduce overdiagnosis and the number of false-positive results while preserving most of the screening benefit. The AUA also recommends that the interval for rescreening may be based on the baseline PSA level. Screening is not recommended for men with life expectancy of less than 10 to 15 years."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_5_3",
"title":{
"__html":"Colorectal Cancer"
},
"titleNode":{
"type":"section-title",
"hlId":"45297c",
"children":[
"Colorectal Cancer"
]
},
"children":[
{
"type":"p",
"hlId":"82f9f1",
"children":[
"There is significant variation in colorectal cancer screening guidelines. The ACP recommends screening for colorectal cancer in asymptomatic adults aged 50 to 75 years (grade A). In contrast, the USPSTF, the U.S. Multi-Society Task Force (MSTF), and the American Cancer Society (ACS) make a qualified recommendation to initiate screening for colorectal cancer at age 45 years. The USPSTF also concludes with moderate certainty that screening for colorectal cancer in adults aged 45 to 49 years has moderate net benefit (Grade B). According to the USPSTF, screening decisions in patients aged 76 to 85 years should be individualized according to life expectancy and ability to tolerate treatment of colorectal cancer if diagnosed. Screening history should also be considered before screening patients in this age group because patients who have not yet undergone screening are the most likely to benefit (grade C). The USPSTF suggests that screening may be discontinued in patients older than 85 years. In contrast, the ACP suggests discontinuing screening in average-risk patients older than 75 years or when the expected life expectancy is less than 10 years."
]
},
{
"type":"p",
"hlId":"22ed75",
"children":[
"There is little head-to-head comparative evidence that any one recommended screening modality provides a greater benefit than the others. In addition, despite unequivocal evidence that colon cancer screening reduces mortality, an estimated one in three U.S. adults who are eligible for colon cancer screening has not been screened. Therefore, the USPSTF supports using the test that is most likely to result in completion of screening. Understanding a patient's values and preferences and selecting a test to which the patient is most likely to adhere may improve screening rates. The ACP suggests a discussion with the patient and consideration of similar factors in selecting a screening strategy. Clinicians should be familiar with the characteristics of each screening strategy to facilitate effective discussion with patients ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t09",
"wrapId":"9",
"children":[
"Table 9"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_b_gm_t09"
]
},
{
"type":"p",
"hlId":"d1a15f",
"children":[
"The ACP suggests colonoscopy every 10 years, flexible sigmoidoscopy every 10 years plus fecal immunochemical testing (FIT) every 2 years, or FIT or high-sensitivity guaiac-based fecal occult blood testing every 2 years as acceptable screening regimens. In contrast, the MSTF, an initiative of U.S. gastroenterology societies, has ranked colorectal cancer screening tests in tiers based on the available evidence, cost-effectiveness, test availability, and several other factors. The MSTF recommends colonoscopy every 10 years or annual FIT as first-tier tests; CT colonography every 5 years, FIT-DNA testing every 3 years, or flexible sigmoidoscopy every 5 to 10 years as second-tier tests; and capsule colonography every 5 years as a third-tier test. The serum circulating methylated ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"SEPT9"
]
},
" DNA test is an FDA-approved screening strategy. However, this test's sensitivity for detecting colorectal cancer is only 48%, and the MSTF does not recommend its use."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_5_4",
"title":{
"__html":"Cervical Cancer"
},
"titleNode":{
"type":"section-title",
"hlId":"f11dca",
"children":[
"Cervical Cancer"
]
},
"children":[
{
"type":"p",
"hlId":"3d9fd1",
"children":[
"The USPSTF recommends screening women aged 21 to 65 years every 3 years with cytology (Pap test). In women aged 30 to 65 years who want to lengthen the screening interval, high-risk human papillomavirus (HPV) testing (preferred) or cytology combined with high-risk HPV testing can be performed every 5 years. The USPSTF recommends against screening women younger than 21 years regardless of sexual history because screening has not been shown to reduce cervical cancer incidence or mortality compared with starting screening at age 21 years."
]
},
{
"type":"p",
"hlId":"a6f62d",
"children":[
"In 2020, the ACS substantially shifted its recommendations for cervical cancer screening to focus on HPV testing. The ACS recommends initiating screening at age 25 years with HPV testing alone (primary HPV testing) every 5 years until age 65 years. When primary HPV testing is unavailable, patients in this age range should preferably be screened with HPV cotesting (HPV testing with cervical cytology) every 5 years, or alternatively with cytology alone every 3 years. Currently, there are two FDA-approved primary HPV tests and five FDA-approved HPV tests for cotesting."
]
},
{
"type":"p",
"hlId":"2725c3",
"children":[
"Screening can be discontinued at age 65 years in non–high-risk women with adequate prior screening, commonly defined as three consecutive negative cytology results or two consecutive negative cytology plus HPV test results within the past 10 years, with the most recent test occurring within 5 years. In women older than 65 years with life expectancy of at least 10 years and risk factors for cervical cancer (history of abnormal Pap smears, history of a high-grade precancerous lesion, in utero exposure to diethylstilbestrol, immunocompromise, previous HPV infection), continued screening should be considered."
]
},
{
"type":"p",
"hlId":"b99acd",
"children":[
"Women who have never been screened have the highest incidence of and mortality from cervical cancer. The mortality reduction from screening in women who have not been previously screened may be as high as 74%. Women older than 65 years who have never been screened or in whom adequacy of prior screening cannot be confirmed should undergo screening with cytology every 3 years, high-risk HPV testing every 5 years, or combined high-risk HPV testing and cytology every 5 years until the criteria for adequate screening have been fulfilled."
]
},
{
"type":"p",
"hlId":"d9bbb8",
"children":[
"Screening should not be performed in women who have had hysterectomy with removal of the cervix unless a high-grade precancerous lesion (cervical intraepithelial neoplasia 2 or 3) was present, in which case screening should be continued for at least 20 years after hysterectomy."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_5_5",
"title":{
"__html":"Lung Cancer"
},
"titleNode":{
"type":"section-title",
"hlId":"487c76",
"children":[
"Lung Cancer"
]
},
"children":[
{
"type":"p",
"hlId":"09f05c",
"children":[
"Although lung cancer screening with chest radiography is not recommended, annual screening with low-dose CT in patients who are heavy smokers results in a 20% to 24% reduction in lung cancer mortality. The USPSTF recommends lung cancer screening with annual low-dose CT for persons aged 50 years to 80 years with a 20-pack-year smoking history; screening should be discontinued in former smokers who have not smoked for 15 years (see ",
{
"type":"cross-reference",
"target":"mk19_b_pm_s7_2_3",
"children":[
"MKSAP 19 Pulmonary and Critical Care Medicine"
]
},
")."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_2_3_5_6",
"title":{
"__html":"Additional Cancer Screening Tests"
},
"titleNode":{
"type":"section-title",
"hlId":"540975",
"children":[
"Additional Cancer Screening Tests"
]
},
"children":[
{
"type":"p",
"hlId":"f210bc",
"children":[
"The USPSTF recommends using a brief familial risk assessment tool, such as the Ontario Family History Assessment Tool, to screen for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1/2"
]
},
" gene mutations risk in patients with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with the mutations. Genetic counseling and possibly genetic testing should be provided to those identified to be at higher risk."
]
},
{
"type":"p",
"hlId":"897c92",
"children":[
"The USPSTF, the Society of Gynecologic Oncology, and the American College of Obstetricians and Gynecologists all recommend against screening for ovarian cancer with serum CA-125 testing or ultrasonography in women at average risk. Women with a family history indicating a possible hereditary cancer syndrome should be referred to a genetic counselor for consideration of genetic testing (see ",
{
"type":"cross-reference",
"target":"mk19_a_on_s2_2",
"children":[
"MKSAP 19 Oncology"
]
},
")."
]
},
{
"type":"p",
"hlId":"b50ae5",
"children":[
"According to the USPSTF, evidence is insufficient to determine the balance of benefits and harms of screening for skin cancer with a visual skin examination (I statement). However, the USPSTF recommends that persons younger than 24 years who have fair skin receive counseling to minimize exposure to ultraviolet radiation to reduce risk for skin cancer (grade B) and recommends offering selective counseling to adults older than age 24 years with fair skin types (grade C)."
]
},
{
"type":"p",
"hlId":"ecf759",
"children":[
"The USPSTF recommends against screening for pancreatic cancer in asymptomatic adults (grade D). Because up to 15% of pancreatic ductal adenocarcinomas are attributable to genetic factors, patients with a family history suggestive of a genetic syndrome associated with pancreatic cancer (",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1/2"
]
},
" mutations, Peutz-Jeghers syndrome, Lynch syndrome) should be referred for genetic counseling and possible genetic testing."
]
},
{
"type":"p",
"hlId":"2188df",
"children":[
"Evidence is insufficient to recommend routine anal cancer screening in average-risk populations, but such screening may be considered in high-risk populations. The Infectious Diseases Society of America suggests screening patients with genital warts, men who have sex with men, and women who have a history of abnormal cervical cytology or participate in receptive anal intercourse."
]
},
{
"type":"p",
"hlId":"66e238",
"children":[
"The USPSTF recommends against screening for testicular cancer and thyroid cancer in asymptomatic adults (grade D). Routine screening for bladder cancer is not recommended by any expert group."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"f98c17",
"children":[
"All women aged 50 to 74 years should undergo screening mammography; the recommended screening interval varies by expert group."
]
},
{
"type":"keypoint",
"hlId":"5664a5",
"children":[
"The ACP recommends screening for colorectal cancer in asymptomatic adults aged 50 to 75 years (grade A); in contrast, the USPSTF and the American Cancer Society (ACS) make a qualified recommendation to initiate screening for colorectal cancer at age 45 years."
]
},
{
"type":"keypoint",
"hlId":"3a6144",
"children":[
"The choice of modality for colorectal cancer screening should be based on discussion with patients, including consideration of likelihood of adherence and patient values and preferences."
]
}
]
}
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_3",
"title":{
"__html":"Immunization"
},
"titleNode":{
"type":"section-title",
"hlId":"a3bca2",
"children":[
"Immunization"
]
},
"children":[
{
"type":"p",
"hlId":"a85be8",
"children":[
"In the United States, annual immunization recommendations are issued by the Advisory Committee on Immunization Practices (ACIP). ACIP recommendations can be accessed at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.cdc.gov/vaccines/acip",
"target":"_blank"
},
"children":[
"www.cdc.gov/vaccines/acip"
]
},
"."
]
},
{
"type":"p",
"hlId":"7b9048",
"children":[
"It is important to adhere to recommended vaccine schedules as closely as possible. Administering doses at longer-than-recommended intervals does not appear to reduce immunologic response; however, doses should not be given at shorter-than-recommended intervals. If a vaccination series is interrupted, it can be resumed at the point of interruption. Whenever possible, multiple vaccines should be given simultaneously to improve vaccination rates."
]
},
{
"type":"p",
"hlId":"51e728",
"children":[
"Vaccines can be safely administered to patients with mild acute febrile illness, those who are convalescing from illness, and those who have previously developed low- or moderate-grade fever or local reactions with vaccination. Vaccines should be avoided if there is a history of anaphylaxis to the vaccine or the vaccine components. Live vaccines and their contraindications are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t10",
"wrapId":"10",
"children":[
"Table 10"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_b_gm_t10"
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_3_1",
"title":{
"__html":"Vaccinations Recommended for All Adults"
},
"titleNode":{
"type":"section-title",
"hlId":"b1546e",
"children":[
"Vaccinations Recommended for All Adults"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_gm_s1_3_1_1",
"title":{
"__html":"Influenza"
},
"titleNode":{
"type":"section-title",
"hlId":"5dc103",
"children":[
"Influenza"
]
},
"children":[
{
"type":"p",
"hlId":"72c456",
"children":[
"Influenza revaccination is necessary each year, owing to frequent genetic changes in the influenza virus (antigenic drift). Annual vaccination is recommended for all individuals aged 6 months or older. In nonpregnant adults, annual vaccination by the end of October is preferred but can be given at any time during the influenza season; “early” vaccination in July and August is not suggested unless later vaccination might not be possible. In pregnant women during the third trimester, however, vaccination may be considered soon after the vaccine becomes available. The live attenuated influenza vaccine is contraindicated in pregnancy and immunocompromised patients and should be used with caution in patients with significant medical conditions, including cardiovascular, pulmonary, or liver disease; dialysis-dependent end-stage kidney disease; or diabetes. A high-dose quadrivalent vaccine became available for the 2020-2021 influenza season for persons aged 65 years or older, replacing the high-dose trivalent vaccine; all influenza vaccines are now quadrivalent. No preferential recommendation is made for one influenza vaccine over another in persons in whom more than one vaccine is appropriate."
]
},
{
"type":"p",
"hlId":"6f2e94",
"children":[
"Persons with a history of egg allergy of any severity can receive any influenza vaccine formulation; however, in persons who have had an egg-related reaction that caused symptoms other than hives, such as angioedema or respiratory distress, the vaccine should be administered by a provider trained in recognizing and managing severe allergic reactions. Persons with a history of Guillain-Barré syndrome related to previous influenza vaccination should not receive additional influenza vaccination."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_3_1_2",
"title":{
"__html":"Tetanus, Diphtheria, and Pertussis"
},
"titleNode":{
"type":"section-title",
"hlId":"db5a4f",
"children":[
"Tetanus, Diphtheria, and Pertussis"
]
},
"children":[
{
"type":"p",
"hlId":"9e95b6",
"children":[
"Primary vaccination against tetanus, diphtheria, and acellular pertussis consists of a five-dose vaccine series administered during childhood. Persons aged 11 to 18 years who have completed the primary series should receive a single dose of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Adults aged 19 years or older who did not receive the Tdap vaccine at age 11 years or older should receive one dose of the Tdap vaccine. In adults who did not receive Tdap at or after age 11 years, one dose of Tdap, then Td or Tdap, is recommended every 10 years."
]
},
{
"type":"p",
"hlId":"1dfb10",
"children":[
"Unvaccinated adults should receive a three-dose series consisting of Td or Tdap, with at least one Tdap dose (preferably as the first dose). Adults who have received fewer than three doses of the primary series should complete the series with the Td or Tdap vaccine, while ensuring that at least one dose of the Tdap vaccine is received."
]
},
{
"type":"p",
"hlId":"149090",
"children":[
"Pregnant women should receive at least one dose of the Tdap vaccine between 27 and 36 weeks' gestation with every pregnancy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_3_2",
"title":{
"__html":"Vaccinations Recommended for Some Adults"
},
"titleNode":{
"type":"section-title",
"hlId":"f83084",
"children":[
"Vaccinations Recommended for Some Adults"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_gm_s1_3_2_1",
"title":{
"__html":"Varicella and Herpes Zoster"
},
"titleNode":{
"type":"section-title",
"hlId":"585773",
"children":[
"Varicella and Herpes Zoster"
]
},
"children":[
{
"type":"p",
"hlId":"4e74ec",
"children":[
"All immunocompetent adults without evidence of varicella immunity should receive two varicella vaccine doses. Evidence of varicella immunity includes laboratory-confirmed disease or immunity, diagnosis or verification of varicella or zoster by a provider, or documentation of age-appropriate varicella vaccination. U.S. birth before 1980 is also considered to be evidence of immunity, except in pregnant women and immunocompromised persons (who are at risk for severe disease) and health care workers (who are at risk for repeated varicella exposure and spreading the disease to those at high risk for severe disease). These patient groups must meet the other criteria for varicella immunity. Although varicella vaccination is contraindicated in patients with severe immunosuppression, it can be considered on the basis of shared clinical decision making in patients with HIV infection and a CD4 percentage greater than or equal to 15% and a CD4 cell count of 200 cells/µL or greater."
]
},
{
"type":"p",
"hlId":"628d6e",
"children":[
"All adults aged 50 years or older, including those with a previous episode of zoster, should receive the recombinant (inactivated) herpes zoster vaccine to reduce the incidence of zoster and postherpetic neuralgia. The recombinant vaccine is also indicated in patients aged 19 years or older at increased risk for zoster because of immunosuppression or immunodeficiency secondary to disease or therapy. It is administered intramuscularly in two doses, with an interval of 2 to 6 months between doses. Vaccination is recommended regardless of previous zoster infection or vaccination with the live vaccine. The safety of the vaccines in pregnant women has not been determined. The ACIP makes no recommendation regarding vaccination during pregnancy other than to consider deferring administration until after pregnancy. The live attenuated vaccine is no longer available in the United States."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_3_2_2",
"title":{
"__html":"Pneumococcal Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"281b04",
"children":[
"Pneumococcal Disease"
]
},
"children":[
{
"type":"p",
"hlId":"0887b4",
"children":[
"Pneumococcal vaccination is recommended in all adults aged 65 years or older and in adults aged 19 to 64 years with certain high-risk conditions ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t11",
"wrapId":"11",
"children":[
"Table 11"
]
}
]
},
")"
]
},
". Three pneumococcal vaccines are available: the 20-valent pneumococcal conjugate vaccine (PCV20), the 15-valent pneumococcal conjugate vaccine (PCV15), and the 23-valent pneumococcal polysaccharide vaccine (PPSV23)."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_b_gm_t11"
]
},
{
"type":"p",
"hlId":"d81cbe",
"children":[
"Patients aged 65 years and older who have not previously received a pneumococcal conjugate vaccine or whose vaccination history is unknown should receive either the PCV20 vaccine alone or the PCV15 vaccine followed by PPSV23 at least 1 year later. Similarly, adults aged 19 to 64 years with high-risk conditions or other risk factors who require vaccination and have not received a pneumococcal conjugate vaccine should receive either PCV20 or the combination of PCV15 and PPSV23. In patients with immunocompromising conditions, the interval between PCV15 and PPSV23 may be shortened to a minimum of 8 weeks."
]
},
{
"type":"p",
"hlId":"00940a",
"children":[
"Eligible patients who had received only PPSV23 previously should receive either PCV15 or PCV20. If given PCV15, there is no need for patients to receive the subsequent PPSV23 vaccination, having received it already in the past."
]
},
{
"type":"p",
"hlId":"010d95",
"children":[
"In patients who have previously received PCV13 or PCV13 with PPSV23, the benefit of receiving PCV15 or PCV20 is unclear. Patients should, however, complete the prior recommended PPSV23 series in follow-up to PCV13. If PPSV23 is unavailable to complete this series, PCV20 may be given."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_3_2_3",
"title":{
"__html":"Human Papillomavirus"
},
"titleNode":{
"type":"section-title",
"hlId":"6d9383",
"children":[
"Human Papillomavirus"
]
},
"children":[
{
"type":"p",
"hlId":"853190",
"children":[
"HPV vaccination prevents persistent HPV infection, which can lead to cervical, anogenital, and nasopharyngeal cancers. A nine-valent HPV vaccine is available and approved for use in both females and males. Patients should be administered the vaccine series at age 11 or 12 years or between the ages of 13 and 26 years if not given previously. In unvaccinated patients aged 27 to 45 years, vaccination can be considered on the basis of risk, using a shared decision-making process. If administered before the age of 15 years, a two-dose series is recommended, whereas a three-dose series is recommended in older individuals. Vaccination is not recommended during pregnancy, although no harmful effects have been noted when inadvertently given to pregnant women and pregnancy testing is not necessary before vaccination."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_3_2_4",
"title":{
"__html":"Measles, Mumps, and Rubella"
},
"titleNode":{
"type":"section-title",
"hlId":"f8c920",
"children":[
"Measles, Mumps, and Rubella"
]
},
"children":[
{
"type":"p",
"hlId":"a3614f",
"children":[
"All U.S. adults born before 1957 are considered immune to measles and mumps. Adults born in 1957 or later without documented evidence of receiving one or more doses of the measles, mumps, and rubella (MMR) vaccine or laboratory-confirmed immunity against all three diseases should receive at least one MMR dose. A second MMR dose should be administered to postsecondary students, household or close personal contacts of immunocompromised persons with no evidence of immunity, and international travelers. For persons who have been previously vaccinated with two doses of a mumps virus–containing vaccine but are at increased risk because of an outbreak, the ACIP recommends administering a third dose of mumps virus–containing vaccine to improve protection."
]
},
{
"type":"p",
"hlId":"2fd4f2",
"children":[
"Health care workers should be considered separately. For those who were born in or after 1957 and who lack evidence of immunity to measles, mumps, or rubella, a two-dose MMR series, with at least 4 weeks between doses, should be administered for measles or mumps immunity, whereas at least a single dose should be administered for rubella immunity. The same administration schedule should be considered in health care workers born before 1957."
]
},
{
"type":"p",
"hlId":"9a8bfe",
"children":[
"In women of childbearing age, it is necessary to determine rubella immunity. Nonpregnant women who lack immunity should be vaccinated. Pregnant women who lack immunity should be vaccinated at the time of delivery before leaving the hospital or at the time of pregnancy termination."
]
},
{
"type":"p",
"hlId":"59b67f",
"children":[
"The MMR vaccine is a live virus vaccine and should not be administered to immunocompromised individuals or pregnant women."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_3_2_5",
"title":{
"__html":"Meningococcal Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"beb8e0",
"children":[
"Meningococcal Disease"
]
},
"children":[
{
"type":"p",
"hlId":"240ced",
"children":[
"Meningococcal vaccines used in the adult population include the quadrivalent meningococcal conjugate vaccine (MenACWY), which protects against serogroups A, C, W135, and Y, and the meningococcal group B (MenB) vaccine, which protects against serogroup B disease. MenACWY is recommended in adolescents aged 11 to 18 years. If the patient was vaccinated at age 11 to 12 years (preferred), a booster dose is administered at age 16 years; if the initial dose was administered at age 13 to 15 years, a booster dose is administered at 16 to 18 years. A booster dose may be administered to persons aged 19 to 21 years who did not receive a dose after age 16 years. If the first dose is administered after age 16 years, a booster dose is not required. First-year college students living in residence halls should receive at least one dose of MenACWY within 5 years before college entry. MenACWY vaccines are interchangeable. Routine two-dose series of MenB can be administered at age 16 to 23 years on basis of shared clinical decision making. A booster dose is not recommended unless the patient develops increased risk for meningococcal disease. MenB vaccines are not interchangeable and dosing schedules differ."
]
},
{
"type":"p",
"hlId":"d2018a",
"children":[
"Indications for meningococcal vaccination in adults at increased risk are summarized in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t12",
"wrapId":"12",
"children":[
"Table 12"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"12",
"contentIds":[
"mk19_b_gm_t12"
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_3_2_6",
"title":{
"__html":"Hepatitis A"
},
"titleNode":{
"type":"section-title",
"hlId":"038690",
"children":[
"Hepatitis A"
]
},
"children":[
{
"type":"p",
"hlId":"022728",
"children":[
"Vaccination against hepatitis A is recommended for all persons who desire vaccination and for persons who are at increased risk for infection or complications of infection, including pregnant women. Persons at increased risk include those who work in or travel to endemic areas, men who have sex with men, individuals with chronic liver disease, individuals with HIV infection, users of injection or noninjection illicit drugs, homeless persons, persons who conduct hepatitis A–related research, household or close contacts of children adopted from endemic areas, and those who work in settings of possible exposure (group homes, nonresidential day-care facilities for developmentally disabled persons, and health care programs serving users of injection or noninjection drugs). Immunization can be provided as a two-dose series of single-antigen hepatitis A vaccine or a three-dose series of combination hepatitis A and B vaccine."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_3_2_7",
"title":{
"__html":"Hepatitis B"
},
"titleNode":{
"type":"section-title",
"hlId":"6836fb",
"children":[
"Hepatitis B"
]
},
"children":[
{
"type":"p",
"hlId":"d3470e",
"children":[
"Hepatitis B vaccination is recommended for all adults aged 19 to 59 years. Vaccination should also be administered to patients aged 60 years and older who desire vaccination or who are considered to be at high risk for infection ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t13",
"wrapId":"13",
"children":[
"Table 13"
]
}
]
},
")"
]
},
". The typical hepatitis B vaccination series is a three-dose series, with doses administered at 0, 1, and 6 months. A vaccine with a novel adjuvant requires only two doses administered at least 4 weeks apart; it appears to be more immunogenic than previous vaccines. Safety data for use of the two-dose vaccine in pregnant women is not available."
]
},
{
"type":"inline-wrap",
"wrapId":"13",
"contentIds":[
"mk19_b_gm_t13"
]
},
{
"type":"p",
"hlId":"117b5a",
"children":[
"Checking serum antibodies is not typically recommended after routine vaccination but is indicated in persons in whom subsequent clinical management is dependent on knowledge of serologic response (e.g., patients on chronic hemodialysis, persons with HIV, health care and public safety workers, and needle-sharing partners of persons who are positive for hepatitis B surface antigen)."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_3_3",
"title":{
"__html":"Vaccinations Recommended for Specific Populations"
},
"titleNode":{
"type":"section-title",
"hlId":"7e3727",
"children":[
"Vaccinations Recommended for Specific Populations"
]
},
"children":[
{
"type":"p",
"hlId":"cfa58c",
"children":[
"Health care workers are at increased risk for acquiring and transmitting hepatitis B, influenza, measles, mumps, rubella, pertussis, and varicella. All health care workers, regardless of patient contact, should receive the influenza vaccine annually. Health care workers without immunity should be vaccinated against hepatitis B; measles, mumps, and rubella; and varicella. In addition, all health care workers who have not previously received the Tdap vaccine should receive one dose, irrespective of when they last received the Td vaccine."
]
},
{
"type":"p",
"hlId":"b0e4a0",
"children":[
"Patients with anatomic or functional asplenia are at increased risk for infection from encapsulated organisms, such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Haemophilus influenzae"
]
},
" type B, meningococcus, and pneumococcus, and should be appropriately vaccinated."
]
},
{
"type":"p",
"hlId":"dcbbe5",
"children":[
"Patients who have undergone hematopoietic stem cell transplantation should receive the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Haemophilus influenzae"
]
},
" type B vaccine."
]
},
{
"type":"p",
"hlId":"c5a256",
"children":[
"Vaccination recommendations for international travelers vary depending on the destination. Trip-specific recommendations from the CDC can be accessed at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://wwwnc.cdc.gov/travel",
"target":"_blank"
},
"children":[
"wwwnc.cdc.gov/travel"
]
},
". For more information on vaccination in travelers, see ",
{
"type":"cross-reference",
"target":"mk19_a_id_s14_1",
"children":[
"MKSAP 19 Infectious Disease"
]
},
"."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"b593ed",
"children":[
"Annual influenza vaccination is recommended for all individuals aged 6 months or older."
]
},
{
"type":"keypoint",
"hlId":"1d8693",
"children":[
"Pregnant women should receive at least one dose of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine between 27 and 36 weeks' gestation with every pregnancy."
]
},
{
"type":"keypoint",
"hlId":"91bb51",
"children":[
"All adults aged 50 years or older should receive the recombinant (inactivated) herpes zoster vaccine, regardless of previous immunization or clinical infection, to reduce the incidence of zoster and postherpetic neuralgia."
]
},
{
"type":"keypoint",
"hlId":"edc57f",
"children":[
"Pneumococcal vaccination is recommended in all adults aged 65 years or older and adults aged 19 to 64 years with certain high-risk conditions."
]
},
{
"type":"keypoint",
"hlId":"289d98",
"children":[
"Patients with anatomic or functional asplenia should be vaccinated against ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Haemophilus influenzae"
]
},
" type B, meningococcal, and pneumococcal diseases."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_4",
"title":{
"__html":"Aspirin for Primary Prevention"
},
"titleNode":{
"type":"section-title",
"hlId":"58c0f4",
"children":[
"Aspirin for Primary Prevention"
]
},
"children":[
{
"type":"p",
"hlId":"f0e7cd",
"children":[
"Because of its low cost and efficacy in preventing cardiovascular and cerebrovascular events, aspirin can be considered for primary prevention of vascular disease. In 2016, the USPSTF recommended low-dose aspirin for the primary prevention of ASCVD and colorectal cancer in willing adults aged 50 to 59 years with a 10-year ASCVD risk of 10% or higher (using the Pooled Cohort Equation risk calculator), a life expectancy of at least 10 years, and no increased risk for bleeding (grade B). The USPSTF suggests individualizing the decision in adults aged 60 to 69 years with a 10-year ASCVD risk of 10% or higher (grade C)."
]
},
{
"type":"p",
"hlId":"28313d",
"children":[
"In 2018, however, three large trials, ASCEND, ARRIVE, and ASPREE, showed that primary prevention with aspirin led to no reduction in nonfatal myocardial infarction or mortality. In 2019, a meta-analysis of the use of aspirin for primary prevention was updated; it included more than 164,000 patients and showed no benefit in any mortality end point. Reductions in nonfatal myocardial infarction (relative risk [RR], 0.82; 0.72-0.94) and ischemic stroke (RR, 0.87; 0.79-0.95) were offset by a significant increase in bleeding events, including major bleeding (RR, 1.5; 1.33-1.69), intracranial bleeding (RR, 1.32; 1.12-1.55), and major gastrointestinal bleeding (RR, 1.52; 1.34-1.73). Subsequently, the ACC/AHA recommended that aspirin should be used infrequently in the routine primary prevention of ASCVD because of lack of net benefit; specifically, low-dose aspirin may be considered for primary prevention of ASCVD in adults aged 40 to 70 years who are at higher ASCVD risk but not at increased bleeding risk. Similarly, the ADA reaffirmed its recommendations in 2019 that low-dose aspirin may be considered in patients with diabetes who are at increased cardiovascular risk."
]
},
{
"type":"p",
"hlId":"5a9e90",
"children":[
"The decision to initiate low-dose aspirin should be informed by the totality of ASCVD risk and bleeding risk as well as patient values and preferences. Factors that increase bleeding risk include concurrent anticoagulant or NSAID use, history of gastrointestinal ulcer, upper gastrointestinal pain, uncontrolled hypertension, male sex, and increasing age. After age 70 years, the benefit of aspirin decreases and bleeding risks are higher; thus, neither the ACC/AHA nor the ADA recommends aspirin for primary prevention in this age group."
]
},
{
"type":"p",
"hlId":"b50a9c",
"children":[
"There is some evidence for the use of aspirin in cancer prevention, with one trial showing a 34% to 40% reduction in colorectal cancer mortality with at least 5 to 10 years of aspirin therapy. The benefit is not apparent until 10 to 20 years after initiation of aspirin; no mortality benefit was observed in the first 10 years of follow-up."
]
},
{
"type":"p",
"hlId":"0d52d6",
"children":[
"Prophylactic aspirin use is also recommended for pregnant women at high risk for preeclampsia and should be considered in those at moderate risk (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s7_2_2",
"children":[
"Women's Health"
]
},
")."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_5",
"title":{
"__html":"Healthy Lifestyle Counseling"
},
"titleNode":{
"type":"section-title",
"hlId":"cf4ee0",
"children":[
"Healthy Lifestyle Counseling"
]
},
"children":[
{
"type":"p",
"hlId":"a4a99d",
"children":[
"Healthy lifestyle counseling is directed at the leading preventable causes of death. Tobacco and obesity contribute significantly to the top two leading causes of death, heart disease and cancer, which account for almost 50% of all deaths in the United States. Other preventable causes of death include alcohol and drug use, infectious diseases, toxins, accidents, and firearms."
]
},
{
"type":"p",
"hlId":"6d5a7c",
"children":[
"Tobacco cessation is a high-priority intervention from a health and cost-effectiveness standpoint. Smokers should be offered pharmacologic therapy and behavioral interventions. For more information, see ",
{
"type":"cross-reference",
"target":"mk19_a_gm_s9_5_1",
"children":[
"MKSAP 19 General Internal Medicine 1"
]
},
"."
]
},
{
"type":"p",
"hlId":"05eef3",
"children":[
"All patients who are overweight or obese should undergo counseling on the benefits of a healthy weight, regular exercise, and a healthy diet (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s1_5_2",
"children":[
"Behavioral Counseling"
]
},
")."
]
},
{
"type":"p",
"hlId":"a44023",
"children":[
"Injury prevention, including seat belt use, use of safety helmets for motorcycles and bicycles, and home safety measures, should be emphasized. Patients should be counseled to use smoke alarms in the home and to set water heaters to lower than 49 °C (120 °F) in households with infants or young children (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t01",
"wrapId":"14",
"children":[
"Table 1"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"14",
"contentIds":[
"mk19_b_gm_t01"
]
},
{
"type":"p",
"hlId":"30e262",
"children":[
"Even small changes at the population level, such as improving social determinants of health, can create large preventive benefits. Healthy People 2020 is a CDC initiative with the goal of creating social and physical environments that promote good health, and Healthy People 2030 is currently in development. Using strategies from behavioral economics, such as making healthy choices the default option or nudging (gently steering people in a certain direction), may improve health outcomes. For example, upon building construction, stairs can be placed front and center and elevators on the side. Sugar- and sodium-laden processed foods shelved at store checkouts can be replaced with fresh fruits and vegetables. Keeping healthy food options in clear containers at home and wrapping unhealthier options in aluminum foil, or not purchasing them altogether, may also be helpful. Pricing and taxation strategies and food stamp programs can help promote the purchase of fruits and vegetables and deter the purchase of unhealthy processed foods, tobacco, and alcohol. Food banks and food pharmacies can also encourage the consumption of fruits and vegetables, especially in urban deserts. Making neighborhoods and cities safer and improving bicycle lanes, walking paths, and stairs may encourage physical activity and reduce inequalities in health."
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_5_1",
"title":{
"__html":"Wellness"
},
"titleNode":{
"type":"section-title",
"hlId":"32a07c",
"children":[
"Wellness"
]
},
"children":[
{
"type":"p",
"hlId":"ae385e",
"children":[
"Sleep and stress reduction are also components of a healthy lifestyle. The AHA and the American Academy of Sleep Medicine recommend that adults sleep at least 7 hours per night for optimal health. Developing effective strategies for stress reduction is an important component of wellness and resiliency. Meditation, mindfulness-based stress reduction, exercise, spending time in nature, strong personal relationships, volunteering, community involvement, cultivating hobbies, and spiritual activities are all associated with better health outcomes. Loneliness and social isolation have been associated with a 29% increase in coronary heart disease and a 32% increase in stroke."
]
},
{
"type":"p",
"hlId":"81d778",
"children":[
"Climate change could cause numerous deleterious effects on human health, including higher rates of respiratory and heat-related illness, skin cancer, increased prevalence of vector-borne (malaria, chikungunya, dengue fever) and waterborne (cholera) diseases, food and water insecurity, and malnutrition. The ACP advises that physicians become educated about climate change, its effect on human health, and how to respond to future challenges."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_5_2",
"title":{
"__html":"Behavioral Counseling"
},
"titleNode":{
"type":"section-title",
"hlId":"c16fc4",
"children":[
"Behavioral Counseling"
]
},
"children":[
{
"type":"p",
"hlId":"315498",
"children":[
"Behavioral counseling is an integral part of helping patients optimize their health and habits. The USPSTF recommends using the 5 A's for clinical counseling for patients regarding tobacco use and cessation: Ask the patient about tobacco use; Advise the patient to quit through clear, personalized messages; Assess the patient's willingness to quit; Assist the patient with their attempt to quit; and Arrange for follow-up and support. Although moderate-intensity (31-360 minutes) and high-intensity (>360 minutes) interventions have shown better results than brief interventions (1-30 minutes), even 1- to 5-minute interventions have proved effective in reducing tobacco use and alcohol misuse."
]
},
{
"type":"p",
"hlId":"2c210b",
"children":[
"The USPSTF also recommends behavioral counseling interventions to promote a healthful diet and physical activity (grade B) for adults who are overweight or obese and have additional risk factors for cardiovascular disease (hypertension, dyslipidemia). For adults who do not meet these criteria, the USPSTF recommends an individualized approach to offering or referring these patients to behavioral counseling to promote a healthy lifestyle, owing to smaller benefits (grade C). Behavior change is inherently difficult because it disrupts the status quo and habits that may have developed over decades. Such strategies as motivational interviewing can be particularly effective in establishing a partnership to create lifestyle changes ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t14",
"wrapId":"15",
"children":[
"Table 14"
]
}
]
},
")"
]
},
". These techniques can help patients identify feasible and desirable steps toward reaching goals. Other helpful strategies include habit replacement; pairing (combining a less desirable activity with a more desirable one, such as only watching television while exercising); and replacing or substituting processed foods with healthier alternatives. Using a multidisciplinary team of health care professionals (dietitians, nurses, and psychologists) can be helpful when available."
]
},
{
"type":"inline-wrap",
"wrapId":"15",
"contentIds":[
"mk19_b_gm_t14"
]
},
{
"type":"p",
"hlId":"7b4a9e",
"children":[
"Behavioral counseling does not need to be complex or time consuming. Studies have shown that patients who were informed of being overweight by their physicians were more likely to report significant weight loss. Advising patients to maintain a healthy weight and adopt healthy practices, including eliminating sugar-containing beverages, implementing a reduced-calorie diet, avoiding processed foods, and practicing mindful eating, can be beneficial (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s1_5_3",
"children":[
"Nutrition"
]
},
" and ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s1_5_4",
"children":[
"Physical Activity"
]
},
"). Providers may also help patients by modeling healthy behaviors; evidence shows that doctors who improve their health habits may be better able to counsel their patients regarding preventive and healthful behaviors."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_5_3",
"title":{
"__html":"Nutrition"
},
"titleNode":{
"type":"section-title",
"hlId":"cf6586",
"children":[
"Nutrition"
]
},
"children":[
{
"type":"p",
"hlId":"2c2efe",
"children":[
"Plant-based and Mediterranean diets as well as consumption of fruits, vegetables, legumes, and vegetable- and lean-animal protein (mostly fish) are consistently associated with lower all-cause mortality than other types of diets and should be the primary components of dietary intake. Dietary guidelines from both the U.S. Department of Health and Human Services and the ACC/AHA recommend following a healthy eating pattern that consists of a variety of vegetables, whole fruits, legumes, nuts, whole grains, and fish while minimizing intake of added sugars, saturated and trans fats, sodium, and refined carbohydrates. Common nutrient deficiencies and associated conditions are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t15",
"wrapId":"16",
"children":[
"Table 15"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"16",
"contentIds":[
"mk19_b_gm_t15"
]
},
{
"type":"p",
"hlId":"8d81f9",
"children":[
"In the Adventist Health Study-2 cohort, consuming meat as a primary source of protein increased mortality by 61% with a corresponding 40% reduction in mortality in those who replaced meat with nuts and seeds as their protein source. Similarly, foods that include trans and saturated fats have consistently been shown to be harmful and increase mortality, and highly processed foods increase the risk for ASCVD and type 2 diabetes."
]
},
{
"type":"p",
"hlId":"26d3d3",
"children":[
"Water should be recommended as the drink of choice. Sugar-containing and artificially sweetened beverages increase the risk for ASCVD and type 2 diabetes. However, artificially sweetened beverages may be a useful replacement for sugar-containing beverages as a transition to drinking water (plain, carbonated, or with unsweetened flavor)."
]
},
{
"type":"p",
"hlId":"9f5c2b",
"children":[
"Adults of legal drinking age should be advised to limit consumption of alcohol to no more than one drink per day for women and two drinks per day for men."
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_5_4",
"title":{
"__html":"Physical Activity"
},
"titleNode":{
"type":"section-title",
"hlId":"5bca63",
"children":[
"Physical Activity"
]
},
"children":[
{
"type":"p",
"hlId":"3d3ade",
"children":[
"Increased physical activity decreases risk for most chronic diseases and cancer. The U.S. Department of Health and Human Services 2018 Physical Activity Guidelines for Americans recommend that adults perform at least 150 to 300 minutes of moderate-intensity or 75 minutes of vigorous-intensity aerobic activity per week, ideally spread throughout the week. Muscle-strengthening activities should be performed at least 2 days per week. Physical activity does not have to take the form of formal exercise or be performed for lengthy intervals. Any physical activity is better than none, and adults should move more and sit less. Patients should be encouraged to discover ways to naturally and habitually incorporate physical activity into their daily life."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_6",
"title":{
"__html":"Supplements and Herbal Therapies"
},
"titleNode":{
"type":"section-title",
"hlId":"e7c110",
"children":[
"Supplements and Herbal Therapies"
]
},
"children":[
{
"type":"p",
"hlId":"c4c8ee",
"children":[
"Dietary supplements, including vitamins, minerals, botanicals, herbals, metabolites, and amino acids, are categorized as foods by the FDA. Therefore, manufacturers are not required to demonstrate efficacy or safety of their products unless the supplement includes ingredients that were introduced after 1994. Manufacturers are not allowed to make specific medical claims; however, the product's intended effect on body structure or function may be described."
]
},
{
"type":"p",
"hlId":"74f4f3",
"children":[
"Patients take dietary supplements for various reasons, such as to prevent and treat illness, manage symptoms, and enhance health. In the United States, approximately 50% of adults report using vitamins or dietary supplements. The USPSTF recommends against the use of β-carotene or vitamin E supplements for the prevention of cardiovascular disease or cancer and has concluded that the current evidence is insufficient to assess the use of multivitamins for the prevention of cardiovascular disease or cancer."
]
},
{
"type":"p",
"hlId":"0f7574",
"children":[
"In general, there is little good-quality evidence showing the efficacy of dietary supplementation, and use carries the potential for harm. There are several populations, however, for which vitamin or supplement use is recommended. Women of childbearing age are advised to take 0.4 to 0.8 mg (400-800 µg) of folic acid daily to prevent fetal neural tube defects. Vegans and older adults may consider vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" supplementation to address dietary deficiency. Calcium and/or vitamin D may also be considered for older adults or individuals with suboptimal bone health. Calcium supplementation may increase the risk for cardiovascular disease and kidney stones, thus eating a calcium-rich diet may be a preferable means of assuring adequate intake. Persons with age-related macular degeneration can take a specific formulation of vitamins, zinc, and copper. Persons taking proton pump inhibitors or metformin can consider supplementation with vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
". Omega-3 fatty acids in fish oils may help hypertriglyceridemia and improve cardiovascular health. Melatonin may be useful for jetlag. Probiotics may be helpful for antibiotic-associated diarrhea, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Clostridioides difficile"
]
},
" infection, ulcerative colitis, and periodontal disease."
]
},
{
"type":"p",
"hlId":"b8e4d2",
"children":[
"Although reports show that multivitamins are the most commonly used supplement, persons eating a well-balanced diet are unlikely to benefit from a multivitamin. Multivitamins should not be used in the absence of a specific indication and are not effective in compensating for a poor diet. Health spas and wellness centers offering intravenous infusions of saline and electrolytes and high-dose vitamins are increasing in popularity. Vaping of vitamins has also been marketed to deliver higher concentrations of vitamins to the body. None of these methods has any evidence supporting their use, and they carry many potential risks."
]
},
{
"type":"p",
"hlId":"404ea2",
"children":[
"In addition to questionable efficacy, supplement use is associated with risk for both direct and indirect harms ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_gm_t16",
"wrapId":"17",
"children":[
"Table 16"
]
}
]
},
")"
]
},
". Direct harms include side effects; interactions with other drugs; and harms related to inclusion of unadvertised additives, compounds, or toxins. Vitamin E, fish oil, and several herbal supplements may interact with anticoagulant or antiplatelet medications, potentially increasing the risk for bleeding or inadequate anticoagulation. Smokers should avoid β-carotene because evidence has linked β-carotene with increased risk for lung cancer. Pregnant women should avoid excessive vitamin A because it has been linked to birth defects. Antioxidant supplements, such as vitamins C and E, may reduce the effectiveness of chemotherapy. Vitamin K, which is a common ingredient in multiple vitamin injections, may decrease the effectiveness of warfarin. Biotin may interfere with serum troponin and thyroid function testing. Harms may also occur indirectly when herbal supplement use replaces or delays standard treatments."
]
},
{
"type":"inline-wrap",
"wrapId":"17",
"contentIds":[
"mk19_b_gm_t16"
]
},
{
"type":"p",
"hlId":"f1e42e",
"children":[
"Despite these risks, many patients strongly believe in supplement use, and the physician's role is to inform these patients of potential side effects. The National Institutes of Health's MedlinePlus directory of herbs and supplements (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://medlineplus.gov/druginfo/herb_All.html",
"target":"_blank"
},
"children":[
"https://medlineplus.gov/druginfo/herb_All.html"
]
},
") and the U.S. Department of Agriculture's website Nutrition.gov (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.nutrition.gov/dietary-supplements",
"target":"_blank"
},
"children":[
"www.nutrition.gov/dietary-supplements"
]
},
") are useful resources."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"9d371a",
"children":[
"Manufacturers of dietary supplements are not required to demonstrate efficacy or safety unless the supplement includes ingredients that were introduced after 1994."
]
},
{
"type":"keypoint",
"hlId":"c0bf68",
"children":[
"Given the prevalence of use and potential for harm, physicians should make inquiring about supplement use a routine component of the medication history."
]
},
{
"type":"keypoint",
"hlId":"92f771",
"hvc":true,
"children":[
"The U.S. Preventive Services Task Force recommends against the use of β-carotene or vitamin E supplements for the prevention of cardiovascular disease or cancer."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_gm_s1_7",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"American College of Obstetricians and Gynecologists Committee on Clinical Practice Guidelines-Gynecology. Osteoporosis prevention, screening, and diagnosis: ACOG clinical practice guideline no. 1. Obstet Gynecol. 2021;138:494-506. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34412075",
"target":"_blank"
},
"children":[
"PMID: 34412075"
]
},
" doi:10.1097/AOG.0000000000004514"
]
},
{
"type":"reference",
"children":[
"American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diabetes Care. 2019;42:S103-23. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30559236",
"target":"_blank"
},
"children":[
"PMID: 30559236"
]
},
" doi:10.2337/dc19-S010"
]
},
{
"type":"reference",
"children":[
"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596-646. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30879355",
"target":"_blank"
},
"children":[
"PMID: 30879355"
]
},
" doi:10.1161/CIR.0000000000000678"
]
},
{
"type":"reference",
"children":[
"Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315:2564-75. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27304597",
"target":"_blank"
},
"children":[
"PMID: 27304597"
]
},
" doi:10.1001/jama.2016.5989"
]
},
{
"type":"reference",
"children":[
"Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force. Screening for obstructive sleep apnea in adults: US Preventive Services Task Force recommendation statement. JAMA. 2017;317:407-14. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28118461",
"target":"_blank"
},
"children":[
"PMID: 28118461"
]
},
" doi:10.1001/jama.2016.20325"
]
},
{
"type":"reference",
"children":[
"Cunningham AL, Lal H, Kovac M, et al; ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019-32. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27626517",
"target":"_blank"
},
"children":[
"PMID: 27626517"
]
},
" doi:10.1056/NEJMoa1603800"
]
},
{
"type":"reference",
"children":[
"Curry SJ, Krist AH, Owens DK, et al; US Preventive Services Task Force. Interventions to prevent perinatal depression: US Preventive Services Task Force recommendation statement. JAMA. 2019;321:580-7. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30747971",
"target":"_blank"
},
"children":[
"PMID: 30747971"
]
},
" doi:10.1001/jama.2019.0007"
]
},
{
"type":"reference",
"children":[
"Curry SJ, Krist AH, Owens DK, et al; US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;320:674-86. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30140884",
"target":"_blank"
},
"children":[
"PMID: 30140884"
]
},
" doi:10.1001/jama.2018.10897"
]
},
{
"type":"reference",
"children":[
"Curry SJ, Krist AH, Owens DK, et al; US Preventive Services Task Force. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA. 2018;319:2521-2531. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29946735",
"target":"_blank"
},
"children":[
"PMID: 29946735"
]
},
" doi:10.1001/jama.2018.7498//"
]
},
{
"type":"reference",
"children":[
"Davidson KW, Barry MJ, Mangione CM, et al; US Preventive Services Task Force. Screening for atrial fibrillation: US Preventive Services Task Force recommendation statement. JAMA. 2022;327:360-367. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/35076659",
"target":"_blank"
},
"children":[
"PMID: 35076659"
]
},
" doi:10.1001/jama.2021.23732"
]
},
{
"type":"reference",
"children":[
"Davidson KW, Barry MJ, Mangione CM, et al; US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:1965-1977. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34003218",
"target":"_blank"
},
"children":[
"PMID: 34003218"
]
},
" doi:10.1001/jama.2021.6238"
]
},
{
"type":"reference",
"children":[
"Davidson KW, Barry MJ, Mangione CM, et al; US Preventive Services Task Force. Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement. JAMA. 2021;326:736-743. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34427594",
"target":"_blank"
},
"children":[
"PMID: 34427594"
]
},
" doi:10.1001/jama.2021.12531"
]
},
{
"type":"reference",
"children":[
"Draznin B, Aroda VR, Bakris G, et al; American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45:S17-S38. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964875",
"target":"_blank"
},
"children":[
"PMID: 34964875"
]
},
" doi:10.2337/dc22-S002"
]
},
{
"type":"reference",
"children":[
"DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635-45. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25119609",
"target":"_blank"
},
"children":[
"PMID: 25119609"
]
},
" doi:10.1056/NEJMoa1315727"
]
},
{
"type":"reference",
"children":[
"Ferket BS, Grootenboer N, Colkesen EB, et al. Systematic review of guidelines on abdominal aortic aneurysm screening. J Vasc Surg. 2012;55:1296-304. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/21324630",
"target":"_blank"
},
"children":[
"PMID: 21324630"
]
},
" doi:10.1016/j.jvs.2010.10.118"
]
},
{
"type":"reference",
"children":[
"Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32729638",
"target":"_blank"
},
"children":[
"PMID: 32729638"
]
},
" doi:10.3322/caac.21628"
]
},
{
"type":"reference",
"children":[
"Freedman MS, Bernstein H, Ault KA. Recommended adult immunization schedule, United States, 2021. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M20-8080",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2021;174:374-84. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33571011",
"target":"_blank"
},
"children":[
"PMID: 33571011"
]
}
]
},
{
"type":"reference",
"children":[
"Ganguli I, Souza J, McWilliams JM, et al. Association of Medicare's annual wellness visit with cancer screening, referrals, utilization, and spending. Health Aff (Millwood). 2019;38:1927-35. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31682513",
"target":"_blank"
},
"children":[
"PMID: 31682513"
]
},
" doi:10.1377/hlthaff.2019.00304"
]
},
{
"type":"reference",
"children":[
"Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 influenza season. MMWR Recomm Rep. 2021;70:1-28. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34448800",
"target":"_blank"
},
"children":[
"PMID: 34448800"
]
},
" doi:10.15585/mmwr.rr7005a1"
]
},
{
"type":"reference",
"children":[
"Grossman DC, Curry SJ, Owens DK, et al; US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319:1901-13. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29801017",
"target":"_blank"
},
"children":[
"PMID: 29801017"
]
},
" doi:10.1001/jama.2018.3710"
]
},
{
"type":"reference",
"children":[
"Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force. Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: US Preventive Services Task Force recommendation statement. JAMA. 2020;324:2069-75. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33231670",
"target":"_blank"
},
"children":[
"PMID: 33231670"
]
},
" doi:10.1001/jama.2020.21749"
]
},
{
"type":"reference",
"children":[
"Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:265-79. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33464343",
"target":"_blank"
},
"children":[
"PMID: 33464343"
]
},
" doi:10.1001/jama.2020.25019"
]
},
{
"type":"reference",
"children":[
"Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force. Screening for asymptomatic carotid artery stenosis: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:476-81. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33528542",
"target":"_blank"
},
"children":[
"PMID: 33528542"
]
},
" doi:10.1001/jama.2020.26988"
]
},
{
"type":"reference",
"children":[
"Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force. Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2020;324:2415-22. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33320230",
"target":"_blank"
},
"children":[
"PMID: 33320230"
]
},
" doi:10.1001/jama.2020.22980"
]
},
{
"type":"reference",
"children":[
"Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force. Screening for hypertension in adults: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2021;325:1650-6. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33904861",
"target":"_blank"
},
"children":[
"PMID: 33904861"
]
},
" doi:10.1001/jama.2021.4987"
]
},
{
"type":"reference",
"children":[
"Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:962-70. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33687470",
"target":"_blank"
},
"children":[
"PMID: 33687470"
]
},
" doi:10.1001/jama.2021.1117"
]
},
{
"type":"reference",
"children":[
"Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force. Screening for unhealthy drug use: US Preventive Services Task Force recommendation statement. JAMA. 2020;323:2301-9. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32515821",
"target":"_blank"
},
"children":[
"PMID: 32515821"
]
},
" doi:10.1001/jama.2020.8020"
]
},
{
"type":"reference",
"children":[
"Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2019;1:CD009009. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30699470",
"target":"_blank"
},
"children":[
"PMID: 30699470"
]
},
" doi:10.1002/14651858.CD009009.pub3"
]
},
{
"type":"reference",
"children":[
"LeFevre ML; U.S. Preventive Services Task Force. Screening for abdominal aortic aneurysm: U.S. Preventive Services Task Force recommendation statement. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M14-1204",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2014;161:281-90. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/24957320",
"target":"_blank"
},
"children":[
"PMID: 24957320"
]
}
]
},
{
"type":"reference",
"children":[
"Manson JE, Bassuk SS. Vitamin and mineral supplements: what clinicians need to know. JAMA. 2018;319:859-60. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29404568",
"target":"_blank"
},
"children":[
"PMID: 29404568"
]
},
" doi:10.1001/jama.2017.21012"
]
},
{
"type":"reference",
"children":[
"Marin M, Marlow M, Moore KL, et al. Recommendation of the Advisory Committee on Immunization Practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak. MMWR Morb Mortal Wkly Rep. 2018;67:33-38. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29324728",
"target":"_blank"
},
"children":[
"PMID: 29324728"
]
},
" doi:10.15585/mmwr.mm6701a7"
]
},
{
"type":"reference",
"children":[
"Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(No. RR-9):1-41. DOI: ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://dx.doi.org/10.15585/mmwr.rr6909a1",
"target":"_blank"
},
"children":[
"http://dx.doi.org/10.15585/mmwr.rr6909a1"
]
}
]
},
{
"type":"reference",
"children":[
"Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:698-702. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31415491",
"target":"_blank"
},
"children":[
"PMID: 31415491"
]
},
" doi:10.15585/mmwr.mm6832a3"
]
},
{
"type":"reference",
"children":[
"Murthy N, Wodi AP, Bernstein H, et al; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2022. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M22-0036",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2022. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/35175828",
"target":"_blank"
},
"children":[
"PMID: 35175828"
]
}
]
},
{
"type":"reference",
"children":[
"Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020;69:1-38. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32614811",
"target":"_blank"
},
"children":[
"PMID: 32614811"
]
},
" doi:10.15585/mmwr.rr6905a1"
]
},
{
"type":"reference",
"children":[
"Oeffinger KC, Fontham ET, Etzioni R, et al; American Cancer Society. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015;314:1599-614. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26501536",
"target":"_blank"
},
"children":[
"PMID: 26501536"
]
},
" doi:10.1001/jama.2015.12783"
]
},
{
"type":"reference",
"children":[
"Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019;322:652-65. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31429903",
"target":"_blank"
},
"children":[
"PMID: 31429903"
]
}
]
},
{
"type":"reference",
"children":[
"Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2020. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32119076",
"target":"_blank"
},
"children":[
"PMID: 32119076"
]
},
" doi:10.1001/jama.2020.1123"
]
},
{
"type":"reference",
"children":[
"Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Screening for HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019;321:2326-36. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31184701",
"target":"_blank"
},
"children":[
"PMID: 31184701"
]
}
]
},
{
"type":"reference",
"children":[
"Patel SG, May FP, Anderson JC, et al. Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2021. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34794816",
"target":"_blank"
},
"children":[
"PMID: 34794816"
]
},
" doi:10.1053/j.gastro.2021.10.007"
]
},
{
"type":"reference",
"children":[
"Piercy KL, Troiano RP, Ballard RM, et al. The physical activity guidelines for Americans. JAMA. 2018;320:2020-8. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30418471",
"target":"_blank"
},
"children":[
"PMID: 30418471"
]
},
" doi:10.1001/jama.2018.14854"
]
},
{
"type":"reference",
"children":[
"Qaseem A, Crandall CJ, Mustafa RA, et al; Clinical Guidelines Committee of the American College of Physicians. Screening for colorectal cancer in asymptomatic average-risk adults: a guidance statement from the American College of Physicians. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M19-0642",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2019;171:643-654. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31683290",
"target":"_blank"
},
"children":[
"PMID: 31683290"
]
}
]
},
{
"type":"reference",
"children":[
"Qaseem A, Lin JS, Mustafa RA, et al; Clinical Guidelines Committee of the American College of Physicians. Screening for breast cancer in average-risk women: a guidance statement from the American College of Physicians. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M18-2147",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2019;170:547-60. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30959525",
"target":"_blank"
},
"children":[
"PMID: 30959525"
]
}
]
},
{
"type":"reference",
"children":[
"Schillie S, Harris A, Link-Gelles R, et al. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67:455-8. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29672472",
"target":"_blank"
},
"children":[
"PMID: 29672472"
]
},
" doi:10.15585/mmwr.mm6715a5"
]
},
{
"type":"reference",
"children":[
"Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29939980",
"target":"_blank"
},
"children":[
"PMID: 29939980"
]
},
" doi:10.15585/mmwr.rr6701a1"
]
},
{
"type":"reference",
"children":[
"Schillie S, Wester C, Osborne M, et al. CDC recommendations for hepatitis C screening among adults—United States, 2020. MMWR Recomm Rep. 2020;69:1-17. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32271723",
"target":"_blank"
},
"children":[
"PMID: 32271723"
]
},
" doi:10.15585/mmwr.rr6902a1"
]
},
{
"type":"reference",
"children":[
"Siu AL; US Preventive Services Task Force. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M15-2345",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2015;163:861-8. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26501513",
"target":"_blank"
},
"children":[
"PMID: 26501513"
]
}
]
},
{
"type":"reference",
"children":[
"Siu AL; U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M15-2886",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2016;164:279-96. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26757170",
"target":"_blank"
},
"children":[
"PMID: 26757170"
]
}
]
},
{
"type":"reference",
"children":[
"Siu AL; U.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M15-2223",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2015;163:778-86. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26458123",
"target":"_blank"
},
"children":[
"PMID: 26458123"
]
}
]
},
{
"type":"reference",
"children":[
"Siu AL, Bibbins-Domingo K, Grossman DC, et al; US Preventive Services Task Force. Screening for depression in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;315:380-7. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26813211",
"target":"_blank"
},
"children":[
"PMID: 26813211"
]
},
" doi:10.1001/jama.2015.18392"
]
},
{
"type":"reference",
"children":[
"Sosa LE, Njie GJ, Lobato MN, et al. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019;68:439-43. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31099768",
"target":"_blank"
},
"children":[
"PMID: 31099768"
]
}
]
},
{
"type":"reference",
"children":[
"Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321:277-87. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30667501",
"target":"_blank"
},
"children":[
"PMID: 30667501"
]
},
" doi:10.1001/jama.2018.20578"
]
},
{
"type":"reference",
"children":[
"Zulman DM, Haverfield MC, Shaw JG, et al. Practices to foster physician presence and connection with patients in the clinical encounter. JAMA. 2020;323:70-81. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31910284",
"target":"_blank"
},
"children":[
"PMID: 31910284"
]
},
" doi:10.1001/jama.2019.19003"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_gm_t01":{
"id":"mk19_b_gm_t01",
"number":1,
"bookId":"gm2",
"title":{
"__html":"Components of the History"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"e76499",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 1. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t01"
}
]
},
"Components of the History"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f874b",
"class":"cell txt l",
"children":[
"Past medical conditions and surgeries"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f889ff",
"class":"cell txt li",
"children":[
"Hospitalizations"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe3c0d",
"class":"cell txt li",
"children":[
"Major childhood illnesses and treatments (e.g., radiation exposure)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dcd7bf",
"class":"cell txt li",
"children":[
"Allergies and corresponding reactions"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7cd9e8",
"class":"cell txt l",
"children":[
"Social history"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c15bde",
"class":"cell txt li",
"children":[
"Alcohol use: frequency and quantity, previous use"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"956d9b",
"class":"cell txt li",
"children":[
"Tobacco use: frequency and quantity, previous use"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"07ba24",
"class":"cell txt li",
"children":[
"Recreational drug use (including marijuana)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4585a6",
"class":"cell txt li",
"children":[
"Spirituality"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bb127d",
"class":"cell txt l",
"children":[
"Work and home situation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8281be",
"class":"cell txt li",
"children":[
"Social support: Does the patient live alone? Whom can the patient call if they have a problem?"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6472ce",
"class":"cell txt li",
"children":[
"Safety"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a5230d",
"class":"cell txt lii",
"children":[
"Home safety"
]
},
" ",
{
"type":"p",
"hlId":"17efdc",
"class":"cell txt liii",
"children":[
"Intimate partner violence in women of reproductive age"
]
},
" ",
{
"type":"p",
"hlId":"32407e",
"class":"cell txt liii",
"children":[
"Working smoke alarms"
]
},
" ",
{
"type":"p",
"hlId":"336596",
"class":"cell txt liii",
"children":[
"Water heater set to ≤49 °C (120 °F)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" ",
{
"type":"p",
"hlId":"5ee5b8",
"class":"cell txt liii",
"children":[
"Weapons: The “5 Ls” for firearm safety counseling in the home: Is it ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"L"
]
},
"ocked? Is it ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"L"
]
},
"oaded? Are there ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"L"
]
},
"ittle children present? Anyone feeling ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"L"
]
},
"ow in the house? Is the operator ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"L"
]
},
"earned about firearm safety?"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9139cd",
"class":"cell txt lii",
"children":[
"Safety while driving"
]
},
" ",
{
"type":"p",
"hlId":"7b7039",
"class":"cell txt liii",
"children":[
"Seatbelt use"
]
},
" ",
{
"type":"p",
"hlId":"714349",
"class":"cell txt liii",
"children":[
"Helmet use while motorcycling or bicycling"
]
},
" ",
{
"type":"p",
"hlId":"3a5c68",
"class":"cell txt liii",
"children":[
"No electronic device use while driving"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4e7b6b",
"class":"cell txt l",
"children":[
"Diet: intake of fruits and vegetables; avoidance of added sugars and processed foods"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"78bd5b",
"class":"cell txt l",
"children":[
"Physical activity"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31f8f0",
"class":"cell txt l",
"children":[
"Family history"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2b43f7",
"class":"cell txt l",
"children":[
"Medication history"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"422671",
"class":"cell txt li",
"children":[
"Prescription (including adherence) and over-the-counter medications"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"757647",
"class":"cell txt li",
"children":[
"Past and current hormone use for transgender patients"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1d866f",
"class":"cell txt li",
"children":[
"Vitamins and supplements"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a35cc",
"class":"cell txt li",
"children":[
"Herbal preparations and nontraditional therapies"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"127391",
"class":"cell txt l",
"children":[
"Sexual history",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd6df3",
"class":"cell txt li",
"children":[
"Partners"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"49c60a",
"class":"cell txt lii",
"children":[
"How many sex partners have you had in the past 2 months? 12 months?"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"13f805",
"class":"cell txt lii",
"children":[
"Have you had sex with men, women, or both?"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6c2e01",
"class":"cell txt li",
"children":[
"Practices"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4475fa",
"class":"cell txt lii",
"children":[
"What kind of sexual contact have you had? Vaginal (penis in vagina), anal (penis in rectum/anus), or oral sex (mouth on penis/vagina)?"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"655ff7",
"class":"cell txt li",
"children":[
"Protection/pregnancy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f721f",
"class":"cell txt lii",
"children":[
"Have you ever had a sexually transmitted infection?"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"72753c",
"class":"cell txt lii",
"children":[
"What do you do to protect yourself from sexually transmitted infections?"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"69286c",
"class":"cell txt lii",
"children":[
"Are you or your partner trying to get pregnant?"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2cbdcf",
"class":"cell txt lii",
"children":[
"What are you doing to prevent pregnancy?"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e1fffd",
"class":"cell txt l",
"children":[
"Review of systems"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"In households with infants and young children."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"When taking a sexual history, do not assume heterosexuality, and use gender-neutral language when referring to partners (“partner” or “spouse” rather than “wife,” “husband,” “girlfriend,” or “boyfriend”)."
]
]
},
"mk19_b_gm_t02":{
"id":"mk19_b_gm_t02",
"number":2,
"bookId":"gm2",
"title":{
"__html":"U.S. Preventive Services Task Force Grading and Suggestions for Practice"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"509161",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 2. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t02"
}
]
},
"U.S. Preventive Services Task Force Grading and Suggestions for Practice"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4b3b9d",
"class":"col hd l",
"children":[
"Grade"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b890b",
"class":"col hd l",
"children":[
"Definition"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"580a66",
"class":"col hd l",
"children":[
"Suggestions for Practice"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7fc562",
"class":"cell txt l",
"children":[
"A"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"35dab6",
"class":"cell txt l",
"children":[
"The USPSTF recommends the service. There is high certainty that the net benefit is substantial."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"803992",
"class":"cell txt l",
"children":[
"Offer or provide this service."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d5ed6",
"class":"cell txt l",
"children":[
"B"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57d19c",
"class":"cell txt l",
"children":[
"The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"803992",
"class":"cell txt l",
"children":[
"Offer or provide this service."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d61f8",
"class":"cell txt l",
"children":[
"C"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ad63e4",
"class":"cell txt l",
"children":[
"The USPSTF recommends selectively offering or providing this service to individual patients based on professional judgment and patient preferences. There is at least moderate certainty that the net benefit is small."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a787dd",
"class":"cell txt l",
"children":[
"Offer or provide this service for selected patients depending on individual circumstances."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f623e7",
"class":"cell txt l",
"children":[
"D"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e3bd2b",
"class":"cell txt l",
"children":[
"The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d88041",
"class":"cell txt l",
"children":[
"Discourage the use of this service."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cf849a",
"class":"cell txt l",
"children":[
"I statement"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5fe21e",
"class":"cell txt l",
"children":[
"The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5bcc36",
"class":"cell txt l",
"children":[
"Read the Clinical Considerations section of USPSTF Recommendation Statement. If the service is offered, patients should understand the uncertainty about the balance of benefits and harms."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"USPSTF = U.S. Preventive Services Task Force."
],
[
"Reproduced from U.S. Preventive Services Task Force. Procedure Manual. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.uspreventiveservicestaskforce.org/Page/Name/procedure-manual",
"target":"_blank"
},
"children":[
"www.uspreventiveservicestaskforce.org/Page/Name/procedure-manual"
]
},
". Accessed June 17, 2021."
]
]
},
"mk19_b_gm_t03":{
"id":"mk19_b_gm_t03",
"number":3,
"bookId":"gm2",
"title":{
"__html":"Risk Factors for Diabetes Mellitus"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"50fe0d",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 3. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t03"
}
]
},
"Risk Factors for Diabetes Mellitus"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c66d8d",
"class":"cell txt l",
"children":[
"First-degree relative with diabetes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b9728",
"class":"cell txt l",
"children":[
"High-risk race/ethnicity"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"648b73",
"class":"cell txt l",
"children":[
"History of cardiovascular disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c779a2",
"class":"cell txt l",
"children":[
"Hypertension (≥140/90 mm Hg or on therapy for hypertension)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bcf320",
"class":"cell txt l",
"children":[
"HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or triglyceride level >250 mg/dL (2.82 mmol/L)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e0eff6",
"class":"cell txt l",
"children":[
"Polycystic ovary syndrome"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d56a5",
"class":"cell txt l",
"children":[
"Physical inactivity"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4e230",
"class":"cell txt l",
"children":[
"Other clinical conditions associated with insulin resistance (e.g., severe obesity, acanthosis nigricans)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"35f7b8",
"class":"cell txt l",
"children":[
"History of gestational diabetes"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Information from Draznin B, Aroda VR, Bakris G, et al; American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45:S17-S38. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964875",
"target":"_blank"
},
"children":[
"PMID: 34964875"
]
},
" doi:10.2337/dc22-S002"
]
]
},
"mk19_b_gm_t04":{
"id":"mk19_b_gm_t04",
"number":4,
"bookId":"gm2",
"title":{
"__html":"U.S. Preventive Services Task Force Recommendations on Screening for Infectious Diseases"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"177d1b",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 4. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t04"
}
]
},
"U.S. Preventive Services Task Force Recommendations on Screening for Infectious Diseases"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7fd029",
"class":"col hd l",
"children":[
"Infectious Disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a801e8",
"class":"col hd l",
"children":[
"Screening Recommendation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2cf297",
"class":"col hd l",
"children":[
"Screening Test"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"321aa3",
"class":"col hd l",
"children":[
"Populations at Risk"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"572412",
"class":"cell txt l",
"children":[
"Chlamydia and gonorrhea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b9c651",
"class":"cell txt l",
"children":[
"Screen all sexually active women aged ≤24 y and women aged >24 y who are at increased risk for infection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"75a872",
"class":"cell txt l",
"children":[
"Nucleic acid amplification test"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c3a7c4",
"class":"cell txt l",
"children":[
"Persons with a history of STIs, persons with new or multiple sexual partners, those who use condoms inconsistently, persons who exchange sex for money or drugs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"abc5a5",
"class":"cell txt l",
"children":[
"HIV"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34057b",
"class":"cell txt l",
"children":[
"Perform one-time screening for all adults aged 15-65 y; repeat screening for adults at increased risk"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"83a630",
"class":"cell txt l",
"children":[
"Combination HIV antibody immunoassay/p24 antigen test"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52a80b",
"class":"cell txt l",
"children":[
"Men who have sex with men, active users of injection drugs, persons who engage in risky behaviors (unprotected vaginal or anal intercourse; sexual partners who are HIV infected, bisexual, or users of injection drugs; transactional sex), persons with other STIs, persons who live and receive care in a high-prevalence setting (HIV seroprevalence of ≥1%)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"03738a",
"class":"cell txt l",
"children":[
"HBV"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32dcc7",
"class":"cell txt l",
"children":[
"Screen all adults at high risk"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1d8a81",
"class":"cell txt l",
"children":[
"Hepatitis B surface antigen test; obtain antibodies (anti-HBs, anti-HBc) to differentiate between immunity and infection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e9d27",
"class":"cell txt l",
"children":[
"Persons born in countries with ≥2% prevalence of HBV infection, persons with HIV infection, users of injection drugs, men who have sex with men, household contacts or sexual partners of persons with HBV infection"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"106ec0",
"class":"cell txt l",
"children":[
"HCV"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"295e67",
"class":"cell txt l",
"children":[
"Perform one-time screening in all patients aged 18-79 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b85e21",
"class":"cell txt l",
"children":[
"Anti-HCV antibody test, followed by PCR viral load test if result is positive"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4c616",
"class":"cell txt l",
"children":[
"Users of injection/intranasal drugs, persons who received a blood transfusion before 1992, persons receiving long-term hemodialysis, prisoners, and persons who received unregulated tattoos"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd36aa",
"class":"cell txt l",
"children":[
"Syphilis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0228da",
"class":"cell txt l",
"children":[
"Screen all adults at increased risk"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"975aea",
"class":"cell txt l",
"children":[
"VDRL or RPR test"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"77fa50",
"class":"cell txt l",
"children":[
"Persons with HIV infection, prisoners, men who have sex with men, persons who exchange sex for money or drugs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d14f9",
"class":"cell txt l",
"children":[
"Latent TB"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a14cdc",
"class":"cell txt l",
"children":[
"Screen populations at increased risk"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6c616f",
"class":"cell txt l",
"children":[
"Tuberculin skin test or interferon-γ release assay"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"23bbd6",
"class":"cell txt l",
"children":[
"Persons born in or former residents of countries with high TB prevalence, close contacts of persons with known or suspected TB, persons who live or work in high-risk settings"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Anti-HBc = hepatitis B core antibody; Anti-HBs = hepatitis B surface antibody; HBV = hepatitis B virus; HCV = hepatitis C virus; PCR = polymerase chain reaction; RPR = rapid plasma reagin; STI = sexually transmitted infection; TB = tuberculosis; VDRL = venereal disease research laboratory."
]
]
},
"mk19_b_gm_t05":{
"id":"mk19_b_gm_t05",
"number":5,
"bookId":"gm2",
"title":{
"__html":"Screening for Infectious Diseases in High-Risk Populations"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"68f087",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 5. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t05"
}
]
},
"Screening for Infectious Diseases in High-Risk Populations"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1c23de",
"class":"col hd l",
"children":[
"Specific Populations"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1d5b5",
"class":"col hd l",
"children":[
"Recommended Screening"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"56d4b1",
"class":"cell txt l",
"children":[
"Pregnant women"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ca5976",
"class":"cell txt l",
"children":[
"Chlamydia and gonorrhea, hepatitis B, HIV, syphilis, asymptomatic bacteriuria"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"986876",
"class":"cell txt l",
"children":[
"Persons engaging in high-risk sexual behavior"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e3cff5",
"class":"cell txt l",
"children":[
"Hepatitis B and C, HIV, syphilis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d5e9ca",
"class":"cell txt l",
"children":[
"Men who have sex with men"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f4c6c",
"class":"cell txt l",
"children":[
"Chlamydia and gonorrhea, hepatitis B, HIV, syphilis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"068fc3",
"class":"cell txt l",
"children":[
"Injection drug users"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"749232",
"class":"cell txt l",
"children":[
"Hepatitis B and C, HIV"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"373220",
"class":"cell txt l",
"children":[
"Prisoners"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"46f8dd",
"class":"cell txt l",
"children":[
"Hepatitis C, hepatitis B",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
", syphilis, tuberculosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5bb49a",
"class":"cell txt l",
"children":[
"Persons receiving hemodialysis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5654f8",
"class":"cell txt l",
"children":[
"Hepatitis B",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
" and C, tuberculosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2f1168",
"class":"cell txt l",
"children":[
"Persons born in or living in countries with ≥2% hepatitis B virus prevalence",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f96a2",
"class":"cell txt l",
"children":[
"Hepatitis B and tuberculosis depending on prevalence of disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f450c",
"class":"cell txt l",
"children":[
"Health care workers"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"01e5a1",
"class":"cell txt l",
"children":[
"Tuberculosis (baseline testing only); pre-employment verification of immunity to hepatitis B virus, measles, mumps, rubella, and varicella"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Recommendations from the Centers for Disease Control and Prevention."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Including most of sub-Saharan Africa, central and southeast Asia, and parts of South America. See ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/hepatitis-b",
"target":"_blank"
},
"children":[
"https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/hepatitis-b"
]
},
" for further details."
]
]
},
"mk19_b_gm_t06":{
"id":"mk19_b_gm_t06",
"number":6,
"bookId":"gm2",
"title":{
"__html":"Recommendations for Breast Cancer Screening in Women at Average Risk"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"1a3b51",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 6. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t06"
}
]
},
"Recommendations for Breast Cancer Screening in Women at Average Risk"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d8198",
"class":"col hd l",
"children":[
"Expert Group"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c76e38",
"class":"col hd l",
"children":[
"Recommendation"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e622cf",
"class":"cell txt l",
"children":[
"American Cancer Society (2015)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f83bfd",
"class":"cell txt l",
"children":[
"Age 40-44 y: Provide women with the opportunity to begin annual screening mammography"
]
},
" ",
{
"type":"p",
"hlId":"0766d0",
"class":"cell txt l",
"children":[
"Age 45-54 y: Perform annual screening mammography"
]
},
" ",
{
"type":"p",
"hlId":"3c6764",
"class":"cell txt l",
"children":[
"Age ≥55 y: Perform biennial screening mammography with the opportunity to continue annual screening"
]
},
" ",
{
"type":"p",
"hlId":"c8f3a2",
"class":"cell txt l",
"children":[
"Do not perform CBE for breast cancer screening"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4b6a38",
"class":"cell txt l",
"children":[
"American College of Obstetricians and Gynecologists (2017)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"11c1ea",
"class":"cell txt l",
"children":[
"Age 25-39 y: May offer CBE every 1-3 y"
]
},
" ",
{
"type":"p",
"hlId":"acf3df",
"class":"cell txt l",
"children":[
"Age 40-49 y: Offer screening mammography and engage women in a shared decision-making process; may offer annual CBE"
]
},
" ",
{
"type":"p",
"hlId":"c0a312",
"class":"cell txt l",
"children":[
"Age 50-75 y: Perform annual or biennial screening mammography based on a shared decision-making process"
]
},
" ",
{
"type":"p",
"hlId":"d5c75a",
"class":"cell txt l",
"children":[
"Age >75 y: Engage women in a shared decision-making process about discontinuing screening"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7d9487",
"class":"cell txt l",
"children":[
"American College of Physicians (2019)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f62d7",
"class":"cell txt l",
"children":[
"Age <40 y: Do not perform screening"
]
},
" ",
{
"type":"p",
"hlId":"74d72c",
"class":"cell txt l",
"children":[
"Age 40-49 y: Potential harms of screening mammography outweigh benefits in average-risk women. Discuss benefits, harms, and patient preferences; order biennial mammography screening only if an informed woman requests it"
]
},
" ",
{
"type":"p",
"hlId":"559572",
"class":"cell txt l",
"children":[
"Age 50-74 y: Encourage biennial mammography screening"
]
},
" ",
{
"type":"p",
"hlId":"6fe99e",
"class":"cell txt l",
"children":[
"Age ≥75 y or life expectancy <10 y: Do not perform screening"
]
},
" ",
{
"type":"p",
"hlId":"219104",
"class":"cell txt l",
"children":[
"Do not use CBE to screen for breast cancer in average-risk women of all ages"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f8005",
"class":"cell txt l",
"children":[
"American College of Radiology (2017)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e7f327",
"class":"cell txt l",
"children":[
"Age 40 y: Begin annual screening mammography"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c458ba",
"class":"cell txt l",
"children":[
"National Comprehensive Cancer Network (2016)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f606d1",
"class":"cell txt l",
"children":[
"Age 25-39 y: Perform CBE every 1-3 y"
]
},
" ",
{
"type":"p",
"hlId":"d92740",
"class":"cell txt l",
"children":[
"Age 40 y: Begin annual screening mammography and perform annual CBE"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c69cf6",
"class":"cell txt l",
"children":[
"U.S. Preventive Services Task Force (2016)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a9ec26",
"class":"cell txt l",
"children":[
"Age 40-49 y: Decision to begin screening should be individualized (grade C)"
]
},
" ",
{
"type":"p",
"hlId":"e60cfe",
"class":"cell txt l",
"children":[
"Age 50-74 y: Perform biennial screening mammography (grade B)"
]
},
" ",
{
"type":"p",
"hlId":"fb94b5",
"class":"cell txt l",
"children":[
"Age ≥75 y: Insufficient evidence to assess the balance of benefits and harms of screening mammography (I statement)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CBE = clinical breast examination."
]
]
},
"mk19_b_gm_t07":{
"id":"mk19_b_gm_t07",
"number":7,
"bookId":"gm2",
"title":{
"__html":"Breast Cancer Deaths Averted per 10,000 Women Screened Over 10 Years"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"f45ba8",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 7. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t07"
}
]
},
"Breast Cancer Deaths Averted per 10,000 Women Screened Over 10 Years"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"5"
},
"children":[
" ",
{
"type":"p",
"hlId":"5bef5e",
"class":"col hd c",
"children":[
"Patient Age"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47c148",
"class":"col hd l",
"children":[
"Variable"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"15e4c6",
"class":"col hd l",
"children":[
"40-49 Years"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d15cc6",
"class":"col hd l",
"children":[
"50-59 Years"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"642706",
"class":"col hd l",
"children":[
"60-69 Years"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4261fa",
"class":"col hd l",
"children":[
"70-74 Years"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e88239",
"class":"cell txt l",
"children":[
"Breast cancer deaths averted (95% CI)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"317b6d",
"class":"cell txt l",
"children":[
"3 (0-9)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"858b0c",
"class":"cell txt l",
"children":[
"8 (2-17)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2d2d52",
"class":"cell txt l",
"children":[
"21 (11-32)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4d7f8",
"class":"cell txt l",
"children":[
"13 (0-32)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"21e99e",
"class":"cell txt l",
"children":[
"NNS for 10 y to avoid one breast cancer death"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2be9bd",
"class":"cell txt l",
"children":[
"3333"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"81e5f8",
"class":"cell txt l",
"children":[
"1250"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"598b3e",
"class":"cell txt l",
"children":[
"476"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"288cc0",
"class":"cell txt l",
"children":[
"769"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"NNS = number needed to screen."
],
[
"Data from Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force recommendation. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M15-0969",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2016;164:244-55. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26756588",
"target":"_blank"
},
"children":[
"PMID: 26756588"
]
}
]
]
},
"mk19_b_gm_t08":{
"id":"mk19_b_gm_t08",
"number":8,
"bookId":"gm2",
"title":{
"__html":"Recommendations for Prostate Cancer Screening"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"430727",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 8. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t08"
}
]
},
"Recommendations for Prostate Cancer Screening"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d8198",
"class":"col hd l",
"children":[
"Expert Group"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c76e38",
"class":"col hd l",
"children":[
"Recommendation"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cd747b",
"class":"cell txt l",
"children":[
"American Cancer Society (2010)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c06e98",
"class":"cell txt l",
"children":[
"Age 40-44 y: Engage men at higher risk (≥2 first-degree relatives with prostate cancer before age 65 y) in shared decision making"
]
},
" ",
{
"type":"p",
"hlId":"24ca8c",
"class":"cell txt l",
"children":[
"Age 45-49 y: Engage men at high risk (African American race or first-degree relative with prostate cancer before age 65 y) in shared decision making"
]
},
" ",
{
"type":"p",
"hlId":"74a145",
"class":"cell txt l",
"children":[
"Age ≥50 y with life expectancy >10 y: Engage in shared decision making"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7bb36f",
"class":"cell txt l",
"children":[
"American College of Physicians (2013)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a7db5c",
"class":"cell txt l",
"children":[
"Age 50-69 y: Inform men about the limited potential benefits and substantial harms of screening for prostate cancer; test only men who request screening after informed discussion"
]
},
" ",
{
"type":"p",
"hlId":"05a57a",
"class":"cell txt l",
"children":[
"Age <50 y, >69 y, or with a life expectancy <10 y: Recommend against screening"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"79679e",
"class":"cell txt l",
"children":[
"American Urological Association (2013; reviewed and confirmed 2015)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e72d95",
"class":"cell txt l",
"children":[
"Men at higher risk (African American race or with positive family history): Individualize screening decisions"
]
},
" ",
{
"type":"p",
"hlId":"37f3dc",
"class":"cell txt l",
"children":[
"Age <40 y: Recommend against screening"
]
},
" ",
{
"type":"p",
"hlId":"1e9a67",
"class":"cell txt l",
"children":[
"Age 40-54 y: Do not recommend routine screening"
]
},
" ",
{
"type":"p",
"hlId":"b8f377",
"class":"cell txt l",
"children":[
"Age 55-69 y: Engage men considering PSA-based screening in shared decision making; proceed on the basis of patient values and preferences. If proceeding with screening, consider PSA testing every 2 y or more"
]
},
" ",
{
"type":"p",
"hlId":"75b732",
"class":"cell txt l",
"children":[
"Age ≥70 y or with life expectancy <10-15 y: Do not recommend routine screening"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2f247a",
"class":"cell txt l",
"children":[
"U.S. Preventive Services Task Force (2018)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4e22f6",
"class":"cell txt l",
"children":[
"Age 55-69 y: Discuss potential benefits and harms of PSA-based screening for prostate cancer and individualize decision making by incorporating the patient's values and preferences"
]
},
" ",
{
"type":"p",
"hlId":"cc49aa",
"class":"cell txt l",
"children":[
"Age ≥70 y: Recommend against PSA-based screening"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"PSA = prostate-specific antigen."
]
]
},
"mk19_b_gm_t09":{
"id":"mk19_b_gm_t09",
"number":9,
"bookId":"gm2",
"title":{
"__html":"Characteristics of Colorectal Cancer Screening Strategies"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"ee1348",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 9. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t09"
}
]
},
"Characteristics of Colorectal Cancer Screening Strategies"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c77951",
"class":"col hd l",
"children":[
"Screening Strategy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7cf395",
"class":"col hd l",
"children":[
"Frequency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"22154e",
"class":"col hd l",
"children":[
"Reduction in Mortality Rate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4c6f8",
"class":"col hd l",
"children":[
"Notes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"b19162",
"class":"col hd l",
"children":[
"Stool-based Tests (Cancer Detection)"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41af5",
"class":"cell txt l",
"children":[
"gFOBT"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bf5808",
"class":"cell txt l",
"children":[
"Every year"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c643d",
"class":"cell txt l",
"children":[
"32%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fcf06f",
"class":"cell txt l",
"children":[
"Performance characteristics of high-sensitivity gFOBT are superior to those of older tests"
]
},
" ",
{
"type":"p",
"hlId":"f97ee4",
"class":"cell txt l",
"children":[
"Requires dietary restrictions; does not require bowel preparation, anesthesia, or transportation to and from the screening examination"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"12197f",
"class":"cell txt l",
"children":[
"FIT"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bf5808",
"class":"cell txt l",
"children":[
"Every year"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"88183b",
"class":"cell txt l",
"children":[
"Unknown"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"796096",
"class":"cell txt l",
"children":[
"Improved accuracy compared with gFOBT"
]
},
" ",
{
"type":"p",
"hlId":"1e7daa",
"class":"cell txt l",
"children":[
"Does not require bowel preparation, anesthesia, or transportation to and from the screening examination"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8b0b25",
"class":"cell txt l",
"children":[
"FIT-DNA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bf142c",
"class":"cell txt l",
"children":[
"Every 1-3 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"88183b",
"class":"cell txt l",
"children":[
"Unknown"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"95c25f",
"class":"cell txt l",
"children":[
"Higher sensitivity but lower specificity than FIT, resulting in more false-positive results"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"f81204",
"class":"col hd l",
"children":[
"Direct Visualization Tests (Cancer Prevention)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"03da23",
"class":"cell txt l",
"children":[
"Colonoscopy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7abb08",
"class":"cell txt l",
"children":[
"Every 10 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10da02",
"class":"cell txt l",
"children":[
"68%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8538c7",
"class":"cell txt l",
"children":[
"Requires full bowel preparation"
]
},
" ",
{
"type":"p",
"hlId":"94d6db",
"class":"cell txt l",
"children":[
"Usually requires sedation and a patient escort"
]
},
" ",
{
"type":"p",
"hlId":"36bd13",
"class":"cell txt l",
"children":[
"ACG/MSTF recommend split-dose preparation",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"076fa7",
"class":"cell txt l",
"children":[
"CT colonography"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10809b",
"class":"cell txt l",
"children":[
"Every 5 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"88183b",
"class":"cell txt l",
"children":[
"Unknown"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"40eafc",
"class":"cell txt l",
"children":[
"Requires bowel preparation"
]
},
" ",
{
"type":"p",
"hlId":"d9d0df",
"class":"cell txt l",
"children":[
"Imaging only (cannot remove polyps or biopsy)"
]
},
" ",
{
"type":"p",
"hlId":"71eec4",
"class":"cell txt l",
"children":[
"Extracolonic findings are common"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c73aef",
"class":"cell txt l",
"children":[
"Flexible sigmoidoscopy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10809b",
"class":"cell txt l",
"children":[
"Every 5 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b323f7",
"class":"cell txt l",
"children":[
"27%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ed7c29",
"class":"cell txt l",
"children":[
"Limited bowel preparation compared with colonoscopy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b0885e",
"class":"cell txt l",
"children":[
"Flexible sigmoidoscopy with FIT"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d89b73",
"class":"cell txt l",
"children":[
"Flexible sigmoidoscopy every 10 y with FIT every year"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b89109",
"class":"cell txt l",
"children":[
"38%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ACG = American College of Gastroenterology; FIT = fecal immunochemical test; gFOBT = guaiac fecal occult blood test; MSTF = U.S. Multi-Society Task Force on Colorectal Cancer."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Split-dose preparation has been shown to increase detection rates for sessile polyps and possibly adenomas. It involves taking half of the preparation the evening before and half of the preparation on the day of colonoscopy, starting 4 to 5 hours before the procedure start and finishing 3 hours before the procedure start."
],
[
"Adapted from Davidson KW, Barry MJ, Mangione CM, et al; US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:1965-1977. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34003218",
"target":"_blank"
},
"children":[
"PMID: 34003218"
]
},
" doi:10.1001/jama.2021.6238"
]
]
},
"mk19_b_gm_t10":{
"id":"mk19_b_gm_t10",
"number":10,
"bookId":"gm2",
"title":{
"__html":"Live Vaccines and Contraindications to Administration"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"69cd08",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 10. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t10"
}
]
},
"Live Vaccines and Contraindications to Administration"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"04b59a",
"class":"col hd l",
"children":[
"Live Vaccines"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"06261f",
"class":"cell txt l",
"children":[
"Live attenuated influenza vaccine (LAIV)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"918546",
"class":"cell txt l",
"children":[
"Measles, mumps, rubella vaccine (MMR)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6981e4",
"class":"cell txt l",
"children":[
"Zoster vaccine live (ZVL)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d8b6fb",
"class":"cell txt l",
"children":[
"Varicella vaccine (VAR)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef81fc",
"class":"col hd l",
"children":[
"Contraindications to Live Vaccines"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e24f9",
"class":"cell txt l",
"children":[
"Pregnancy or probable pregnancy within 4 wk"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"75b8f3",
"class":"cell txt l",
"children":[
"HIV with CD4 cell count ≤200 cells/µL or CD4 cells ≤15% of total lymphocytes",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cd9212",
"class":"cell txt l",
"children":[
"Immunosuppressant therapy, including high-dose glucocorticoids (≥20 mg/d of prednisone or equivalent for ≥2 wk)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"227fa9",
"class":"cell txt l",
"children":[
"Leukemia, lymphoma, or other bone marrow and lymphatic system malignancies"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97f479",
"class":"cell txt l",
"children":[
"Cellular immunodeficiency"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fc7fc0",
"class":"cell txt l",
"children":[
"Solid-organ transplant recipient"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e218b",
"class":"cell txt l",
"children":[
"Recent hematopoietic stem cell transplantation"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Zoster vaccine live (ZVL) is no longer available in the United States."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Live attenuated influenza vaccine is contraindicated in patients with HIV infection regardless of CD4 cell count."
]
]
},
"mk19_b_gm_t11":{
"id":"mk19_b_gm_t11",
"number":11,
"bookId":"gm2",
"title":{
"__html":"Indications for Pneumococcal Vaccination Recommendations for Adults Aged 19 to 64 Years"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"291a98",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 11. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t11"
}
]
},
"Indications for Pneumococcal Vaccination Recommendations for Adults Aged 19 to 64 Years"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e94be",
"class":"col hd l",
"children":[
"Risk Group"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"230bdf",
"class":"col hd l",
"children":[
"Underlying Medical Condition"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6418df",
"class":"cell txt l",
"children":[
"Immunocompetent persons"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"daa738",
"class":"cell txt l",
"children":[
"Chronic heart disease",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" ",
{
"type":"p",
"hlId":"425493",
"class":"cell txt l",
"children":[
"Chronic lung disease",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" ",
{
"type":"p",
"hlId":"05159a",
"class":"cell txt l",
"children":[
"Diabetes mellitus"
]
},
" ",
{
"type":"p",
"hlId":"e2f095",
"class":"cell txt l",
"children":[
"CSF leaks"
]
},
" ",
{
"type":"p",
"hlId":"701a02",
"class":"cell txt l",
"children":[
"Cochlear implants"
]
},
" ",
{
"type":"p",
"hlId":"9d3d0d",
"class":"cell txt l",
"children":[
"Alcoholism"
]
},
" ",
{
"type":"p",
"hlId":"3d6bcf",
"class":"cell txt l",
"children":[
"Chronic liver disease"
]
},
" ",
{
"type":"p",
"hlId":"b4b099",
"class":"cell txt l",
"children":[
"Cigarette smoking"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a561f2",
"class":"cell txt l",
"children":[
"Persons with functional or anatomic asplenia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"04926d",
"class":"cell txt l",
"children":[
"Sickle cell disease/other hemoglobinopathies"
]
},
" ",
{
"type":"p",
"hlId":"76ebb8",
"class":"cell txt l",
"children":[
"Congenital or acquired asplenia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2f2dd4",
"class":"cell txt l",
"children":[
"Immunocompromised persons"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8aa561",
"class":"cell txt l",
"children":[
"Congenital or acquired immunodeficiencies",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" ",
{
"type":"p",
"hlId":"80a1d1",
"class":"cell txt l",
"children":[
"HIV infection"
]
},
" ",
{
"type":"p",
"hlId":"070143",
"class":"cell txt l",
"children":[
"Chronic kidney failure"
]
},
" ",
{
"type":"p",
"hlId":"91cfff",
"class":"cell txt l",
"children":[
"Nephrotic syndrome"
]
},
" ",
{
"type":"p",
"hlId":"425f3a",
"class":"cell txt l",
"children":[
"Leukemia; lymphoma; Hodgkin lymphoma"
]
},
" ",
{
"type":"p",
"hlId":"8ea5c9",
"class":"cell txt l",
"children":[
"Multiple myeloma"
]
},
" ",
{
"type":"p",
"hlId":"586ff4",
"class":"cell txt l",
"children":[
"Generalized malignancy"
]
},
" ",
{
"type":"p",
"hlId":"814637",
"class":"cell txt l",
"children":[
"Iatrogenic immunosuppression",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" ",
{
"type":"p",
"hlId":"f74b48",
"class":"cell txt l",
"children":[
"Solid-organ transplant"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CSF = cerebrospinal fluid."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Including heart failure and cardiomyopathies."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Including COPD, emphysema, and asthma."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Including B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease)."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Including diseases requiring treatment with immunosuppressive drugs, including long-term systemic glucocorticoids and radiation therapy."
],
[
"Adapted from Centers for Disease Control and Prevention (CDC). Murthy N, Wodi AP, Bernstein H, et al; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2022. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M22-0036",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2022. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/35175828",
"target":"_blank"
},
"children":[
"PMID: 35175828"
]
}
]
]
},
"mk19_b_gm_t12":{
"id":"mk19_b_gm_t12",
"number":12,
"bookId":"gm2",
"title":{
"__html":"Indications for Meningococcal Vaccination in Adults with Increased Risk for Meningococcal Disease"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"f43a73",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 12. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t12"
}
]
},
"Indications for Meningococcal Vaccination in Adults with Increased Risk for Meningococcal Disease"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"13e038",
"class":"col hd l",
"children":[
"Population"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"12ef7d",
"class":"col hd l",
"children":[
"MenACWY"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd83c9",
"class":"col hd l",
"children":[
"MenB"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"073f1e",
"class":"cell txt l",
"children":[
"Persistent complement component deficiencies (C5-C9, factor H, factor D, properdin) or persons taking complement inhibitors (e.g, eculizumab or ravulizumab)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a7a0f7",
"class":"cell txt l",
"children":[
"Primary vaccination followed by booster every 5 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9dfc43",
"class":"cell txt l",
"children":[
"Primary vaccination followed by booster 1 y later and every 2-3 y thereafter"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"92c5d6",
"class":"cell txt l",
"children":[
"Functional or anatomic asplenia (including sickle cell disease)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a7a0f7",
"class":"cell txt l",
"children":[
"Primary vaccination followed by booster every 5 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9dfc43",
"class":"cell txt l",
"children":[
"Primary vaccination followed by booster 1 y later and every 2-3 y thereafter"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"80a1d1",
"class":"cell txt l",
"children":[
"HIV infection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a7a0f7",
"class":"cell txt l",
"children":[
"Primary vaccination followed by booster every 5 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"961da1",
"class":"cell txt l",
"children":[
"Same as general population"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b295f9",
"class":"cell txt l",
"children":[
"Microbiologists routinely exposed to ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Neisseria meningitidis"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a7a0f7",
"class":"cell txt l",
"children":[
"Primary vaccination followed by booster every 5 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9dfc43",
"class":"cell txt l",
"children":[
"Primary vaccination followed by booster 1 y later and every 2-3 y thereafter"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ebb170",
"class":"cell txt l",
"children":[
"Exposure to vaccine-preventable serogroup meningococcal disease outbreak"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a159ac",
"class":"cell txt l",
"children":[
"Single dose if ≥5 y since vaccination"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f08ea2",
"class":"cell txt l",
"children":[
"Primary vaccination; booster if ≥1 y since primary series"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"36e3fd",
"class":"cell txt l",
"children":[
"Travel or residence in country with hyperendemic or epidemic meningococcal disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a7a0f7",
"class":"cell txt l",
"children":[
"Primary vaccination followed by booster every 5 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"961da1",
"class":"cell txt l",
"children":[
"Same as general population"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d820f",
"class":"cell txt l",
"children":[
"College freshmen living in residence halls"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a93531",
"class":"cell txt l",
"children":[
"Primary vaccination"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"961da1",
"class":"cell txt l",
"children":[
"Same as general population"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aa2c95",
"class":"cell txt l",
"children":[
"Military recruits"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"22de55",
"class":"cell txt l",
"children":[
"Primary vaccination followed by booster every 5 y (depending on military assignment)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"961da1",
"class":"cell txt l",
"children":[
"Same as general population"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"MenACWY = meningococcal groups A, C, W, and Y; MenB = meningococcal group B."
],
[
"Adapted from Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69:1-41. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33417592",
"target":"_blank"
},
"children":[
"PMID: 33417592"
]
},
" doi:10.15585/mmwr.rr6909a1"
]
]
},
"mk19_b_gm_t13":{
"id":"mk19_b_gm_t13",
"number":13,
"bookId":"gm2",
"title":{
"__html":"Populations With an Indication for Hepatitis B Vaccination"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"db907f",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 13. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t13"
}
]
},
"Populations With an Indication for Hepatitis B Vaccination"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4e88dc",
"class":"cell txt l",
"children":[
"Any nonimmune adult desiring vaccination"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"606045",
"class":"cell txt l",
"children":[
"Sexually active persons who are not in a monogamous relationship (any person with more than one sexual partner within the past 6 mo)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ca84e",
"class":"cell txt l",
"children":[
"Persons seeking evaluation or treatment for a sexually transmitted infection"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0a5685",
"class":"cell txt l",
"children":[
"Sexual partners of persons who are HBsAg positive"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d5e9ca",
"class":"cell txt l",
"children":[
"Men who have sex with men"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b5daf4",
"class":"cell txt l",
"children":[
"Household contacts of persons who are HBsAg positive"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d9997",
"class":"cell txt l",
"children":[
"Residents and staff members of institutions for persons who are developmentally disabled"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a19fae",
"class":"cell txt l",
"children":[
"Persons who are current or recent users of injection drugs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"38d1b6",
"class":"cell txt l",
"children":[
"Health care and public safety workers with anticipated risk for exposure"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e30934",
"class":"cell txt l",
"children":[
"Persons with end-stage kidney disease, including those receiving hemodialysis and peritoneal dialysis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f3e779",
"class":"cell txt l",
"children":[
"International travelers to regions with intermediate or high levels of endemic hepatitis B infection"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-12 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f74260",
"class":"cell txt l",
"children":[
"Persons with chronic liver disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-13 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dfd2e0",
"class":"cell txt l",
"children":[
"Persons with HIV infection"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-14 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e42238",
"class":"cell txt l",
"children":[
"Persons with diabetes mellitus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-15 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"53b227",
"class":"cell txt l",
"children":[
"Incarcerated persons"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"HBsAg = hepatitis B surface antigen."
]
]
},
"mk19_b_gm_t14":{
"id":"mk19_b_gm_t14",
"number":14,
"bookId":"gm2",
"title":{
"__html":"Motivational Interviewing"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"ed4302",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 14. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t14"
}
]
},
"Motivational Interviewing"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac4d18",
"class":"cell txt l",
"children":[
"Engage"
]
},
" ",
{
"type":"p",
"hlId":"22eab4",
"class":"cell txt li",
"children":[
"Obtain a genuine understanding of the patient's behavior in a nonjudgmental way."
]
},
" ",
{
"type":"p",
"hlId":"6e8c3f",
"class":"cell txt li",
"children":[
"Reflect back what the patient says, using slightly different wording, to facilitate understanding and establish rapport."
]
},
" ",
{
"type":"p",
"hlId":"7dd2b7",
"class":"cell txt li",
"children":[
"Avoid making assumptions about the patient's motivation."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e24ee2",
"class":"cell txt l",
"children":[
"Focus"
]
},
" ",
{
"type":"p",
"hlId":"607550",
"class":"cell txt li",
"children":[
"Listen and practice ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"change talk"
]
},
" (giving positive reasons for changing the behavior) versus ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"sustain talk"
]
},
" (explaining why the patient might want to sustain the behavior)."
]
},
" ",
{
"type":"p",
"hlId":"5fa9cb",
"class":"cell txt li",
"children":[
"Acknowledge ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"sustain talk"
]
},
" and gently encourage the patient to elaborate during ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"change talk"
]
},
":"
]
},
" ",
{
"type":"p",
"hlId":"c43b13",
"class":"cell txt lii",
"children":[
"Elaborate: “Tell me more.” “Yes, I see.”"
]
},
" ",
{
"type":"p",
"hlId":"1f1323",
"class":"cell txt lii",
"children":[
"Affirm: “You want to be a good role model for your children.”"
]
},
" ",
{
"type":"p",
"hlId":"0f2de7",
"class":"cell txt lii",
"children":[
"Reflect: “It sounds like that really affected you.” “You're going to start running again.”"
]
},
" ",
{
"type":"p",
"hlId":"7c96de",
"class":"cell txt lii",
"children":[
"When reflecting, make a guess in the form of a statement."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b828a",
"class":"cell txt l",
"children":[
"Evoke"
]
},
" ",
{
"type":"p",
"hlId":"b61af3",
"class":"cell txt li",
"children":[
"Help patient formulate and verbalize their new goals, what they are hoping for, reasons to change, and what would be a good first step."
]
},
" ",
{
"type":"p",
"hlId":"c26eb8",
"class":"cell txt li",
"children":[
"If patient feels unable to express goals, hopes, and/or reasons to change, offer suggestions of what other patients have done in similar situations."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b6cbd",
"class":"cell txt l",
"children":[
"Plan"
]
},
" ",
{
"type":"p",
"hlId":"63026d",
"class":"cell txt li",
"children":[
"Discuss specific goals and resources to achieve goals and parameters for monitoring progress and evaluating success."
]
},
" ",
{
"type":"p",
"hlId":"386238",
"class":"cell txt li",
"children":[
"Identify barriers to success and make a plan to combat these barriers in advance."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_gm_t15":{
"id":"mk19_b_gm_t15",
"number":15,
"bookId":"gm2",
"title":{
"__html":"Common Nutrient Deficiencies"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"d45758",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 15. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t15"
}
]
},
"Common Nutrient Deficiencies"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"918f09",
"class":"col hd l",
"children":[
"Nutrient Deficiency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bf2eb9",
"class":"col hd l",
"children":[
"Associated Disease/Disorder and Manifestations"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b2acd",
"class":"cell txt l",
"children":[
"Vitamin D"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"016b89",
"class":"cell txt l",
"children":[
"Osteoporosis, fractures, weakness"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a9640c",
"class":"cell txt l",
"children":[
"Calcium"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"016b89",
"class":"cell txt l",
"children":[
"Osteoporosis, fractures, weakness"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c7a445",
"class":"cell txt l",
"children":[
"Vitamin C"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f962cb",
"class":"cell txt l",
"children":[
"Scurvy: perifollicular hemorrhage, poor wound healing, gingivitis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cefa8a",
"class":"cell txt l",
"children":[
"Iron"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fc45c6",
"class":"cell txt l",
"children":[
"Anemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5c5639",
"class":"cell txt l",
"children":[
"Folate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fc45c6",
"class":"cell txt l",
"children":[
"Anemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f559a",
"class":"cell txt l",
"children":[
"Vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b0360f",
"class":"cell txt l",
"children":[
"Anemia, mental status and psychiatric changes, subacute combined degeneration of the dorsal and lateral spinal cord column"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"41b213",
"class":"cell txt l",
"children":[
"Pyridoxine (vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"6"
]
},
")"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d2d0aa",
"class":"cell txt l",
"children":[
"Skin problems, neuropathy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52cb91",
"class":"cell txt l",
"children":[
"Thiamine (vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
")"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"557c14",
"class":"cell txt l",
"children":[
"Beriberi, Wernicke-Korsakoff syndrome: peripheral neuropathy, heart failure, nystagmus, ataxia, ophthalmoplegia, encephalopathy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"deddf9",
"class":"cell txt l",
"children":[
"Vitamin K"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"abab4a",
"class":"cell txt l",
"children":[
"Coagulopathy, elevated INR"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"55cf08",
"class":"cell txt l",
"children":[
"Vitamin A"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d22e2c",
"class":"cell txt l",
"children":[
"Dry eyes, dry skin, night blindness"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7cb447",
"class":"cell txt l",
"children":[
"Dietary fiber"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ddc531",
"class":"cell txt l",
"children":[
"Intestinal problems"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_gm_t16":{
"id":"mk19_b_gm_t16",
"number":16,
"bookId":"gm2",
"title":{
"__html":"Common Herbal Supplements"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a495c2",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 16. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t16"
}
]
},
"Common Herbal Supplements"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"49ee30",
"class":"col hd l",
"children":[
"Name"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e4ef36",
"class":"col hd l",
"children":[
"Common Uses"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2e0c72",
"class":"col hd l",
"children":[
"Effectiveness"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8bc11",
"class":"col hd l",
"children":[
"Adverse Effects"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1d5578",
"class":"col hd l",
"children":[
"Important Drug Interactions"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2e6fc7",
"class":"cell txt l",
"children":[
"Black cohosh"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e6e74b",
"class":"cell txt l",
"children":[
"Treatment of menopausal hot flashes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dfdb2d",
"class":"cell txt l",
"children":[
"Probably effective, low-quality evidence"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d32661",
"class":"cell txt l",
"children":[
"Possible estrogenic effect on breast"
]
},
" ",
{
"type":"p",
"hlId":"ca1efb",
"class":"cell txt l",
"children":[
"Avoid in women with estrogen receptor–positive breast cancer"
]
},
" ",
{
"type":"p",
"hlId":"54332b",
"class":"cell txt l",
"children":[
"Reports of hepatotoxicity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9830f3",
"class":"cell txt l",
"children":[
"Cranberry"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"230e21",
"class":"cell txt l",
"children":[
"Prevention of urinary tract infections"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"00cb04",
"class":"cell txt l",
"children":[
"Probably ineffective; low-quality evidence"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b05e96",
"class":"cell txt l",
"children":[
"Increased glucose intake with juice, GI upset"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f6dccd",
"class":"cell txt l",
"children":[
"Echinacea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"932b02",
"class":"cell txt l",
"children":[
"Prevention of common colds"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8868d8",
"class":"cell txt l",
"children":[
"Small effect"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e7a805",
"class":"cell txt l",
"children":[
"GI upset, nausea, allergic reactions"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c0cf33",
"class":"cell txt l",
"children":[
"Treatment of common colds"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90ac71",
"class":"cell txt l",
"children":[
"Not effective"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bead46",
"class":"cell txt l",
"children":[
"Evening primrose oil"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"00f50d",
"class":"cell txt l",
"children":[
"Treatment of breast pain"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ac6fc",
"class":"cell txt l",
"children":[
"Mixed data on effectiveness"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4980d",
"class":"cell txt l",
"children":[
"GI upset, headache"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3ccd01",
"class":"cell txt l",
"children":[
"May increase bleeding if used with warfarin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f8dd3",
"class":"cell txt l",
"children":[
"Treatment of eczema"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90ac71",
"class":"cell txt l",
"children":[
"Not effective"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d96acd",
"class":"cell txt l",
"children":[
"May increase risk for pregnancy complications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"156e1f",
"class":"cell txt l",
"children":[
"Treatment of diabetic neuropathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5aca58",
"class":"cell txt l",
"children":[
"Possibly effective"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26f556",
"class":"cell txt l",
"children":[
"Garlic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"39e159",
"class":"cell txt l",
"children":[
"Treatment of high cholesterol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90ac71",
"class":"cell txt l",
"children":[
"Not effective"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a587d1",
"class":"cell txt l",
"children":[
"Increased bleeding risk, breath and body odor, heartburn"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d8ef0",
"class":"cell txt l",
"children":[
"May decrease effectiveness of isoniazid and saquinavir"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f4871",
"class":"cell txt l",
"children":[
"Treatment of hypertension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac8241",
"class":"cell txt l",
"children":[
"Possibly effective; weak evidence"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b7f4ef",
"class":"cell txt l",
"children":[
"May increase bleeding if used with warfarin, likely due to antiplatelet effect"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"63e336",
"class":"cell txt l",
"children":[
"Ginger"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4cc27a",
"class":"cell txt l",
"children":[
"Treatment of nausea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a093d3",
"class":"cell txt l",
"children":[
"Probably effective for pregnancy-related and chemotherapy-related nausea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e15576",
"class":"cell txt l",
"children":[
"Increased bleeding"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1a3093",
"class":"cell txt l",
"children":[
"May increase risk for bleeding when used with anticoagulants"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a07be",
"class":"cell txt l",
"children":[
"Treatment of inflammation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5aca58",
"class":"cell txt l",
"children":[
"Possibly effective"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"773ebd",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Ginkgo biloba"
]
},
" "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"687e14",
"class":"cell txt l",
"children":[
"Treatment and prevention of cognitive decline"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90ac71",
"class":"cell txt l",
"children":[
"Not effective"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6edd83",
"class":"cell txt l",
"children":[
"Headache, GI upset, allergic skin reactions, increased risk for bleeding"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"21d58b",
"class":"cell txt l",
"children":[
"May increase risk for bleeding when used with anticoagulants and NSAIDs; potentiates MAOIs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"869c41",
"class":"cell txt l",
"children":[
"Treatment of claudication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90ac71",
"class":"cell txt l",
"children":[
"Not effective"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"359d67",
"class":"cell txt l",
"children":[
"Kava"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8e061d",
"class":"cell txt l",
"children":[
"Treatment of anxiety"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0254e3",
"class":"cell txt l",
"children":[
"Probably effective"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"929937",
"class":"cell txt l",
"children":[
"Hepatotoxicity"
]
},
" ",
{
"type":"p",
"hlId":"467514",
"class":"cell txt l",
"children":[
"Use with caution in patients with liver disease or at risk for liver disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5b54a0",
"class":"cell txt l",
"children":[
"Milk thistle"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b688ef",
"class":"cell txt l",
"children":[
"Reduction in liver inflammation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90ac71",
"class":"cell txt l",
"children":[
"Not effective"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"53233f",
"class":"cell txt l",
"children":[
"Nausea, indigestion, diarrhea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"39c2e1",
"class":"cell txt l",
"children":[
"May interact with medications metabolized by CYP2C9"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"020c6c",
"class":"cell txt l",
"children":[
"Red yeast rice (contains monacolin K, identical active ingredient to lovastatin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cc71e5",
"class":"cell txt l",
"children":[
"Treatment of hyperlipidemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"545b7e",
"class":"cell txt l",
"children":[
"Probably effective; risks likely to outweigh benefits"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fc360f",
"class":"cell txt l",
"children":[
"Myalgia, liver function abnormalities"
]
},
" ",
{
"type":"p",
"hlId":"60685f",
"class":"cell txt l",
"children":[
"Some may contain citrinin (a harmful contaminant), which can cause kidney failure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4f174",
"class":"cell txt l",
"children":[
"May interact with medications metabolized by CYP3A4 enzymes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"99bc2c",
"class":"cell txt l",
"children":[
"Saw palmetto"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6339a3",
"class":"cell txt l",
"children":[
"Treatment of benign prostatic hyperplasia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0930a1",
"class":"cell txt l",
"children":[
"Probably not effective"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4323f8",
"class":"cell txt l",
"children":[
"Headache, nausea, dizziness"
]
},
" ",
{
"type":"p",
"hlId":"62ce5d",
"class":"cell txt l",
"children":[
"Contraindicated in pregnancy and lactation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-12 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"920d39",
"class":"cell txt l",
"children":[
"Soy (isoflavones)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f6fd70",
"class":"cell txt l",
"children":[
"Treatment of menopausal symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fbddeb",
"class":"cell txt l",
"children":[
"Probably effective; low-quality evidence"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"892f5b",
"class":"cell txt l",
"children":[
"GI upset, allergic reaction"
]
},
" ",
{
"type":"p",
"hlId":"3402d4",
"class":"cell txt l",
"children":[
"Avoid high doses in patients with breast cancer"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-13 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7fb147",
"class":"cell txt l",
"children":[
"St. John's wort"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c281dc",
"class":"cell txt l",
"children":[
"Treatment of depression"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ac6fc",
"class":"cell txt l",
"children":[
"Mixed data on effectiveness"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"650f1c",
"class":"cell txt l",
"children":[
"GI upset, fatigue, headache, dizziness"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a95286",
"class":"cell txt l",
"children":[
"Inducer of CYP3A4 and CYP2C9 enzymes"
]
},
" ",
{
"type":"p",
"hlId":"640afc",
"class":"cell txt l",
"children":[
"Many interactions"
]
},
" ",
{
"type":"p",
"hlId":"2481fb",
"class":"cell txt l",
"children":[
"Do not use with antidepressants"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-14 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c3db8b",
"class":"cell txt l",
"children":[
"Valerian"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8e061d",
"class":"cell txt l",
"children":[
"Treatment of anxiety"
]
},
" ",
{
"type":"p",
"hlId":"e0a561",
"class":"cell txt l",
"children":[
"Treatment of sleep disorders, insomnia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"725038",
"class":"cell txt l",
"children":[
"Not effective; evidence is inconclusive"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"834b41",
"class":"cell txt l",
"children":[
"Tremor, headache, sedation, hepatotoxicity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CYP2C9 = cytochrome P450 2C9; CYP3A4 = cytochrome P450 3A4; GI = gastrointestinal; MAOI = monoamine oxidase inhibitor."
]
]
}
}
}